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ABSTRACT
The transcription factor Pax-5 is a member o f the pax, or paired box, family of
genes and is a key regulator in the development, activation and proliferation of B
lymphocytes. The pax-5 gene is alternatively spliced resulting in four isoforms: the fulllength isoform Pax-5a and three alternative isoforms, Pax-5b, Pax-5d and Pax-5e.
Alternative isoform Pax-5 e has been shown to enhance the activity of Pax-5 a in a dosedependent manner, resulting in increased cell proliferation in vitro. Based on this
information, we hypothesized that if Pax-5e were overexpressed in a murine system that
we would see increases in B cell proliferation as well as possible changes in Pax-5a target
gene expression.
We generated two lines of transgenic mice overexpressing Pax-5e, TG5e-7 and
TG5e-49. Analysis o f RNA expression of the transgene indicated that TG5e-7 mice
express the transgene in B cells only, while TG5e-49 expresses the transgene in both B
and T cell lineages. Cultured bone marrow cells from both strains of mice revealed
increases in cell proliferation as compared to negative controls. We also showed that
after immunization, TG5e-7 mice have increased numbers o f CD19+ B cells and IgGsecreting cells as well as an overall increase in secreted IgG and IgM. TG5e-49 mice
displayed decreases in CD 19+ B cells as well as CD3+ T cells after immunization. This
strain also showed a decrease in the levels of secreted IgG. No change in the number of
Ig-secreting cells was observed but a shift toward smaller ELISPOTS was evident.
Immunized TG5e-49 mice, but not TG5e-7, also revealed overexpression of Pax-5a target
gene, CD19, by “real time” PCR.
Our data supports the hypothesis that overexpression of Pax-5e increases the
activity of Pax-5a thus resulting in changes in target gene expression and increased cell
proliferation. Immunization of transgenic mice reveals a more striking phenotype than
found in unimmunized mice indicating that development and activation of lymphocytes
are greatly affected by overexpression of Pax-5e. Our in vivo data have provided
evidence that Pax-5e plays an important role in the regulation of Pax-5 a during B cell
development, activation and proliferation.

THE EFFECTS OF OVEREXPRESSION ALTERNATIVE ISOFORM PAX-5E
IN VIVO

CHAPTER I
Literature Review
The immune system is essential for defense against foreign antigens as it mediates
the removal of those antigens from the body. B lymphocytes are unique immune cells in
that they express surface immunoglobulin (Ig), or B cell receptors (BCR), which bind to
antigen with extreme specificity. Once an antigen has bound to a BCR, this triggers a
cascade of events leading to the activation of the cell, followed by the proliferation and
differentiation into Ig-secreting plasma cells and memory cells.
Many mechanisms control development and activation of B cells. Developmental
cues include extracellular growth factors and cell-cell contacts as well as stage-specific
intracellular control by transcription factors. Combinatorial regulation of transcription
factors dictates the developmental stage of the B cell, as well as whether the cell should
proceed to the next stage or arrest and undergo apoptosis. The realm of B cell
development and function has been under investigation for decades as these cells are
crucial to immune function. The use of mice carrying targeted mutations has allowed
scientists to manipulate molecular pathways within the B cell and has led to a better
understanding of the roles of transcription factors essential for proper B cell development
and function. Uncontrolled B cell populations can lead to leukemia, lymphoma,
autoimmune disease, or immune deficiency thus, the treatment of many diseases relies on
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understanding how B cell transcription factors function within the cell. The focus of this
research was to determine the role(s) of transcription factor Pax-5e, an alternative
isoform of the Pax-5a factor, in B cell development and proliferation in vivo.

B Lymphocyte Development
B lymphopoiesis involves a complex network of transcription factors and
extracellular signaling molecules that work together to transform a hematopoietic stem
cell into a mature B cell capable of producing antigen-specific surface immunoglobulins
(Ig) (Figure 1.1). This process occurs within the fetal liver and adult bone marrow of
mammals and is antigen-independent (Busslinger, 2004; Bartholdy & Matthias, 2004;
Smith & Sigvardsson, 2004). Hematopoietic stem cells commit to a lymphoid lineage
through the expression of the Ets family transcription factor PU. 1 and will give rise to
one of three types of lymphoid cells including B, T and Natural Killer (NK) cells. The
Ikaros gene isoforms are also crucial to lymphoid development as mice carrying targeted
disruption of this gene fail to produce B cells and show significant disruption in T cell
differentiation (Reya & Grosschedl, 1998). Ikaros and family members, Helios and
Aiolos, may also play a role in gene silencing and chromatin remodeling.
The transcription factors E2A and early B cell factor (EBF) are necessary for the
induction o f pax-5 gene expression in B cell progenitors (Bain et al., 1994; Lin &
Grosschedl, 1995). The combination of E2A, EBF and Pax-5 regulate the proliferation
and differentiation of lymphoid progenitors into the earliest form of B cell, the progenitor
B cell (pro-B cell) (Busslinger, 2004; Bartholdy & Matthias, 2004; Smith & Sigvardsson,
2004). Early pro-B cells express the transmembrane protein tyrosine kinase B220 (or

4
CD45R) and surface antigens CD43 and CD 19, and their Ig genes remain in germline
configuration (Busslinger, 2004; Smith & Sigvardsson, 2004). It is late in this stage that
Ig gene rearrangement, the hallmark of B cell development, is initiated resulting in the
rearrangement of D h -J h segments o f the IgH locus (Figure LI; Nutt et al., 1997; Reya &
Grosschedl, 1998; Bartholdy & Matthias, 2003; Busslinger, 2004; Smith & Sigvardsson,
2004). Gene rearrangement results from the expression of the recombinase proteins
RAG-1 and RAG-2 which splice out segments of the Ig loci at recombination signal
sequences. Leading into the early precursor B cell (pre-B I cell) stage, the cell completes
V h -D J h

rearrangement of the IgH locus and a pre-BCR is expressed on the cell surface.

The pre-BCR consists of a fully rearranged IgH chain, surrogate light chains X5 and
VpreB as well as receptor accessory peptides Iga (mb-1) and IgP (B-29).
During the pre-B I cell stage, cells express the surface antigens CD20, CD22 and
CD72, as well as intracellular signaling molecules such as B lymphoid kinase (Blk),
which are all involved in pre-BCR signaling (Figure LI; Liberg and Sigvardsson, 1999).
Later in the pre-B II segment of the pre-B cell stage, CD 19, an accessory protein
involved in pre-BCR signaling, is expressed on the cell surface. Pre-BCR signaling
influences positive selection of those pre-B cells that possess a functional IgH gene
rearrangement, while those cells that fail to accomplish this undergo programmed cell
death or apoptosis (Melchers et al., 1995). The Ig light chain (IgL) locus undergoes VLJ l rearrangement

later in this stage, also called the pre-B II stage, to produce functional X

and k light chains (Figure 1.1; Liberg and Sigvardsson, 1999; Maier & Hagman, 2002).
Following the completion of IgL gene rearrangement, the pre-B cell can now form a
functional BCR and enter the next developmental stage, the immature B cell stage.

Antigen Dependent Stages

Figure LI: Stages of B lymphocyte development. Each stage of B cell development is characterized by
rearrangement of the IgH and IgL loci as well as the expression of stage specific genes
(GL=germline) (Maier & Hagman, 2002; Liberg & Sigvardsson, 1999).

Antigen Independent Stages
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Immature B cells, defined as expressing fully functional membrane-bound IgM
with particular antigen specificity, leave the bone marrow and follow the blood stream to
the secondary lymphoid organs such as spleen and lymph nodes. During this time, they
undergo negative selection for autoreactivity (Liberg and Sigvardsson, 1999). Those
cells which respond to self antigens can initiate receptor editing of their IgL, and if they
are still autoreactive after editing, development is arrested and these cells are eliminated
by apoptosis (Levine et al., 2000). Once a cell has passed the selection process and
expresses membrane-bound IgD, it has reached the mature B cell stage capable of
responding to antigen.
Mature B cells migrate to the secondary lymphoid organs, namely the spleen and
lymph nodes, where they remain in a resting state until activated by a foreign antigen
(reviewed in Rudin & Thompson, 1998). Each B cell contains BCRs with specificity to a
certain sequence of peptides or antigen, and when this particular antigen binds the BCR,
the cell becomes activated. B cells can become activated via T cell-dependent or T cellindependent pathways. T cell-dependent activation requires crosslinking of the B cell
antigen receptor complex. Activation of B cells also occurs in the absence of T cell
activity (so called T cell-independent activation) by means of direct stimulation by
extracellular cytokines released in the presence of B cell-specific mitogens (i.e.
lipopolysaccharide). Activated B cells form germinal centers in secondary lymphoid
organs where they undergo a number of transcriptional changes that lead to cell
proliferation, Ig isotype switching, affinity maturation through somatic hypermutation,
and generation of plasma effector cells and/or memory B cells (Liberg & Sigvardsson,
1999; Hagman et al., 2000).
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Differentiation of an activated B cell into a plasma cell is dependent on
expression of different transcription factors including B lymphocyte-induced maturation
protein-1 (Blimp-1) (Figure 1.1; Shaffer et al., 2002). Plasma cells and their precursors,
the plasmablasts, are characterized by their ability to secrete immunoglobulin molecules.
Upon differentiation of an activated B cell into a plasmablast, these cells migrate from
the germinal centers to the splenic pulp or bone marrow where they continue to mature
and secrete antibodies (Calame et al., 2003). Terminally differentiated plasma cells
display an increase in surface expression of Syndecan-1 and tumor necrosis factor family
receptor OX40L, as well as enlarged rough endoplasmic reticulum ideal for mass
production of secreted proteins. Though plasma cells possess immunoglobulins, they
lack a BCR and other signaling molecules including CD19, CD21, CD 22 and CD45.
Activated B cells can also take on a memory cell fate. Although there is evidence
that activated B cells possessing a BCR o f extremely high affinity to the specific antigen
will favor differentiation into a plasma cell, expression o f CD40 favors a memory cell
fate (Calame et al., 2003). Memory cells are long-lived cells, surviving in the spleen and
tonsils for months and possibly years. They are characterized by expression of surface
receptor CD27 as well as a diverse selection of affinity matured membrane-bound IgG
isotypes (Agematsu et al., 2000). Differentiation of an activated B cell to a memory B
cell within germinal centers is influenced by many extracellular cytokine signals or
receptor ligands (e.g., CD40L) (Arpin et al., 1995). In time, these cells may encounter
their target antigen again resulting in rapid activation, proliferation and differentiation
into plasma cells thus mounting a more efficient “secondary” immune response.
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Pax-5
The Pax gene family. Though there are many transcription factors that direct B
lymphopoiesis, B cell specific activator protein (BSAP) or Pax-5 is one of the master
regulators from the pro-B cell through the plasmablast stage (Figure 1.1; Hagman et al.,
2000). Due to the importance of Pax-5 in B cell development and proliferation,
understanding its role was the focus o f this thesis research. Pax-5 is a member of the
paired box-containing family of transcription factors (TF) which produces TFs that
regulate many aspects of organogenesis, morphogenesis and development in both
vertebrates and invertebrates (Chi & Epstein, 2002). The Pea gene family includes Pax
proteins 1-9, all of which contain a highly conserved N-terminal sequence of 128 amino
acids that comprises a DNA-binding domain, the “paired domain” (Walther et al., 1991;
Chi & Epstein, 2002). Based on both sequence and structural similarity, as well as on the
presence or absence of the octamer and homeodomain regions, the Pax proteins have
been grouped into four subgroups (Figure 1.2; Dahl et al., 1997).
All members of the four groups contain the highly conserved N-terminal paired
domain; however, they may vary in other structural aspects (Figure 1.2). The octamer
sequence is found in groups I-III. In Pax-5, this sequence is known to interact with Grg4,
a member of the Groucho family o f corepressors, to mediate Pax-5 target gene repression
(Eberhard et al., 2000). The homeodomain, which defines these pea genes as homeobox
genes, is found in its complete form in groups III and IV, and in partial form in group II
(Balczarek et al., 1997; Dahl et al., 1997). Each of these transcription factors are
involved in regulating normal development of vertebrates. Development of the central
nervous system requires regulation by Pax-1-3, 5, 7-9 (Dahl et al., 1997; Schwarz et al.,

Paired Domain

Group I

Pax-1
Pax-9

]V

Group II

p ax-2
Pax-5
Pax-8

jy.

Group III

Pax-3
Pax-7

]\

Group IV

Pax-4
Pax-6

Octamer

Homeodomain

Figure 1.2: Structures of protein members of the Pax family of genes. The nine pax
genes give rise to different proteins which are all related by structure. These structures
have allowed these genes and their products to be classified into four distinct groups
shown above with a list of the particular gene products found within the group. All
groups contain a highly conserved DNA-binding motif, the paired domain. The paired
domain in each group is depicted by a different color pattern due to the fact that binding
specificity is different for each group. The homeodomain region is found in groups II, III
and IV, with group II containing only a partial homeodomain. The octamer (or
octapeptide) sequence is found in groups I-III; this domain may have a role in proteinprotein interactions.
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1997) with Pax-2 and 8 playing fundamental roles in kidney development as well (Chi &
Epstein, 2002). Pax-4 plays a crucial role in endocrine development and function, while
Pax-6 regulates eye morphogenesis.
Members of Group II, containing Pax-2/5/8, share such extremely high sequence
homology in the paired domain motif (90-95%), that it may be possible these proteins can
bind many of the same DNA target sequences and thus may potentially create
redundancy within the subgroup (Walther et al., 1991). Evidence for this is provided by
studies using targeted mutations in one or the other protein and analysis of brain
phenotypes of mice expressing different levels o f each protein which show conserved
function between Pax-2 and Pax-5 in midbrain and cerebellum development (Schwarz et
al., 1997). This could explain why all three perform similar roles during CNS
development as well as why both Pax2 and Pax8 control kidney development.

Pax-5: origin and function. B cell-specific activator protein (BSAP) was first described
in a B cell line as a mammalian homolog to the previously described tissue-specific
activator protein (TSAP), a transcription factor responsible for different developmental
processes in the sea urchin (Barberis et al., 1990). BSAP was found to be expressed in all
B cell stages except plasma cells. Further characterization and homology screening of
BSAP revealed that it is encoded by the pax-5 gene in mammals (Adams et al., 1992).
Since then, Pax-5 (now known as Pax-5a) and its role in B cell development have been
extensively studied, as it is the only member of the Pax family involved in hematopoiesis.
The Pax-5 protein is a 53kDa transcription factor with a complete 128 amino acid
N-terminal paired DNA-binding domain which forms a bipartite structure comprised of
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two helix-tum-helices (Maier & Hagman, 2002). This m otif allows Pax-5 to interact with
the bases of the major groove of the DNA within a promoter region. A serine/threoninerich C-terminal /nms-activating domain contributes to Pax5’s ability to activate or
repress target genes, while the partial homeodomain and complete octapeptide sequence
mediate protein-protein interactions (Adams et al., 1992; Maier & Hagman, 2002).
Although expressed in the developing CNS as well as the adult testis, Pax-5
expression is more pronounced in the B-lymphoid tissues (Adams et al., 1992). Pax-5 is
expressed during all stages o f B cell development through maturity and activation;
however, it is down regulated once an activated B cell has committed to a plasma cell
fate (Barberis et al., 1990). Repression of Pax-5 during plasma cell development is
controlled via B lymphocyte induced maturation protein-1 (Blimp-1) (Lin et al., 2002).
Experiments using Pax-5-deficient mice revealed a complete block of B lymphopoiesis at
the end of the pro-B stage resulting in the absence of immature and mature B cells
(Urbanek et al., 1994). These mice are unable to mount a humoral immune response and
lack germinal centers within secondary lymphoid tissues. Also, in the absence of Pax-5,
pro-B (Nutt et al., 1998) as well as pre-B cells (Mikkola et al., 2002) will default to a
myeloid or T cell lineage. Both experiments conclude that Pax-5 must be continuously
expressed in order to maintain commitment to a B cell lineage.
Pax-5 maintains B cell lineage commitment by acting as a “master regulator” of
many important B cell-specific genes. Pax-5 binding sites have been identified on
promoters of these putative target genes: CD19, mb-1, PD-1, LEF-, N-myc, c-myc (Nutt
et al., 1998), immunoglobulin joining chain (J chain) (Wallin et al, 1999), XBP-1
(Reimold et al, 1996), RAG-2 ( Kishi et al., 2002) and notch-1 (Souabni, et al., 2002).
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Pax-5 also regulates the transcription of pre-BCR components such as VpreB and X5 of
the surrogate light chain (Tian et al., 1997). Before rearrangement of the IgL kappa gene,
a transcription o f the gene does occur, producing what is called a sterile transcript
(Lennon & Perry, 1990). This is a germline-configuration transcript of the

k

light chain

gene which is not translated until complete rearrangement of the gene has occurred. Pax5 is responsible for sterile transcription of the

k

light chain during IgL rearrangement

(Sato et al., 2004).
What makes Pax-5 interesting is its ability to act as either a transcriptional
activator or repressor. Among some of the target genes repressed by Pax5 are M-CSFR,
notch-1 and XBP-1. During early pro-B development, expression of such transcription
factors as E2A and EBF are not sufficient to commit to a B cell lineage. Commitment to
the B lineage by Pax-5 involves preventing a response to the myeloid cytokine M-CSF as
well as T lymphoid specific notch-1 ligands, by repression of M-CSFR (Busslinger, 2004)
and Notch-1 (Souabni et al., 2002), respectively. During B cell development, Pax-5 also
appears to repress XBP-1 which is essential for driving plasma cell differentiation as the
emergence of Pax-5-repressor Blimp-1 relieves repression of XBP-1 (Shaffer et al., 2002).

The role of Pax-5 in B cell proliferation. Pax-5 has been shown to have a distinct role
in B cell proliferation. By transfecting splenic B cells with a BSAP expression plasmid
and incubating the cells with one o f three proliferative stimuli (LPS, CD40 ligand or antiIgD), Max et al (1995) showed that increased amounts of transfected BSAP caused an
increase in proliferation as measured by 3H-thymidine incorporation. Data from
electrophoretic mobility shift assays (EMSA) revealed increased BSAP activity that
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correlated with the increase in proliferation. To address whether down-regulated Pax-5
would show a decrease in proliferation, splenic B cells were incubated with the same
three proliferative stimuli as well as varying concentrations of BSAP antisense
oligonucleotides (oligo) or control sense oligonucleotides. Increasing antisense oligo
concentrations showed a significant decrease in BSAP activity. Similarly, B cell
proliferation was severely impaired by increasing amounts of the antisense oligo, as
compared to no significant effect from the control sense oligo. Finally, transfection of
plasmacytoma cell line MOPC315 with a BSAP expression construct also caused an
increase in proliferation, suggesting that Pax-5/BSAP is sufficient to stimulate
proliferation in non-B cells (Max et al., 1995).
Among the genes positively regulated by Pax-5 is the B-lymphoid tyrosine kinase
(blk) gene which contains Pax-5 binding sites in its promoter region (Liberg &
Sigvardsson, 1999). Blk has also been shown to play a dynamic role in B cell activation
and proliferation (Malek et al, 1998). Blk is a member o f the Src tyrosine kinase
subfamily of proteins associated with the T or B cell receptor; Blk is specifically
expressed in the B cell lineage. Activation of the Blk protein, or family members Fyn
and Lyn, is triggered by stimulation of the BCR (Saijo et al, 2003). This may play a role
in NF-kB activation, which is associated with B cell activation after binding to antigen as
was shown in mice deficient for Blk/Fyn/Lyn. Knockout of these three genes was
necessary as mice deficient for each individual protein showed no change in phenotype
from wild-type mice. This suggests that Blk, Fyn and Lyn play redundant roles in NF-kB
induction and B cell activation (Saijo et al., 2003). Transgenic mice overexpressing a
constitutively active form of the Blk protein, in B and/or T cell lineages, produced tumors
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originating from lymphoid progenitor cells in the spleen and bone marrow (Malek et al.,
1998). The transgenic construct also caused Blk expression in T cells, which initiated
tumor formation in the thymus. This suggests that Blk has a role not only in B cell
activation but also in B cell proliferation during development.

Alternative Isoforms of Pax-5. In 1997 it was discovered that the pax5 gene is
alternatively spliced into four isoforms; Pax-5a, Pax-5b, Pax-5d and Pax-5e (Figure 1.3)
(Zwollo et al., 1997). Though each alternative isoform is important for B cell function,
the focus of this research was to determine the in vivo role o f Pax-5e in B cell
development and proliferation. The full-length variant Pax-5 or BSAP is now known as
Pax-5a. The other variants code for proteins with a variety of deleted or novel segments.
Pax-5b and -5e transcripts contain incomplete DNA-binding domains lacking exon 2 (nt
47-212). Pax-5d and -5e transcripts have spliced out exons 6-10 (the C-terminal
transactivating domain and partial homeodomain), which have been replaced by a novel
sequence of unknown origin. The position of this novel sequence in the pax-5 gene has
yet to be determined however; in Pax-5d and -5e transcripts it is comprised of 128
nucleotides and shares homology with the coding region in a number of oxidoreductases.
Each of the four proteins is expressed at different levels during B cell development; Pax5a is the most prominent isoform. Pax-5d and -5e are expressed at very low levels, but
this also varies during B cell development as Pax-5e levels increase after 4-6 day
stimulation of splenic cells with LPS (Lowen et al., 2001).
To form alternatively spliced isoforms, a gene (or mRNA) requires a splice site
(or stop codon) to inform transcriptional (or translational) machinery where one isoform
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Figure 1.3: Alternative isoforms of Pax-5. The gene for the transcription factor Pax-5
generates four isoforms: main isoform Pax-5a (53kDa), and three alternative isoforms
Pax-5b (41kDa), Pax-5d (31kDa) and Pax-5e (19kDa). Here, Pax-5/BSAP, the full
length protein, is referred to as Pax-5 a. Each o f the other isoforms contains a different
combination of the domains found in Pax-5 a. Diagonally striped boxes show the DNAbinding domain, calles the paired domain (aa 16-143). Pax-5b and 5e each have a partial
paired domain as these proteins are produced from the second translational start site
(indicated by ATG-2). Hatched boxes represent the Octamer sequence (aa 179-186)
which is conserved in all isoforms. Wavy line boxes indicate the homeodomain (aa 229251); Shaded boxes indicate the transactivation domain (aa 304-358); Black boxes
indicate the repression domain (aa 358-391). Both Pax-5d and 5e contain a novel
sequence (Checkered boxes, aa 203-244) of unknown origin and lack the homeodomain,
transactivation and repression domains on their C-terminus.
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stops and another starts. The pax-5 gene contains a splice site between nucleotides 606
and 607 which also corresponds to the intron-exon boundary flanked by exons 5 and

6

(Zwollo et al., 1997). Exon 5 encodes the octapeptide sequence (nucleotides 535-558)
which is found on all Pax-5 proteins, while exon 6 encodes the partial homeodomain
(nucleotides 685-753) found only on Pax-5a and -5b. This splice site produces isoforms
Pax-5d and -5e which lack the partial homeodomain yet still retain the octapeptide
sequence. Retaining the octamer sequence may allow Pax-5d or -5e to interact with
members of the Groucho corepressor family, as Pax-5 a interacts with Grg4 through the
octamer (Eberhard et al., 2000)

Pax-5e: characteristics and possible roles. The Pax-5e protein is predicted to be 1819kDa based on amino acid sequence; however, western blots reveal that this protein
preferentially runs at 27-29kDa (Lowen et al., 2001). Based on this information, it is
hypothesized that Pax-5e either forms a secondary structure in the cell, forms
homodimers, or associates with another small protein. To answer these questions, a
mutant form o f Pax-5e was created using PCR-directed site-specific mutagenesis. In the
mutant, called Pax-5e.mC5, the most C-terminal of the three cysteine residues was
replaced by a structurally similar serine, making the mutant constitutively reduced. The
Pax-5e.mC5 was transfected into NTE13T3 cells and, when followed by western blot
analysis, the mutant Pax-5e ran completely at the 19kDa position. This indicates that
Pax-5e may normally be in an oxidized form while the mutant lacking the third cysteine
residue remains reduced. If Pax-5e does interact with another small protein, it is possible
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that only the oxidized form o f 5e can create this heterodimer, as the 27-29kDa band was
not present when the mutant protein was used.
Transcription factors and other proteins can be regulated in several ways; in
particular oxidation/reduction (or redox) modifications can alter protein activity states.
Redox regulation occurs by changing the oxidation state of cysteine residues found on the
protein; oxidized cysteine residues are bound to one another in a disulfide bond, while
reduced cysteines remain unbound (Tell et al., 2000). Proteins such as Ref-1 and
thioredoxin (TRX) are enzymes capable of reducing their substrate during episodes of
oxidative stress (Hirota et al., 1997). Thus, proteins reduced by Ref-l/TRX will continue
to function in a heavily oxidized environment.
Previous studies have shown that Pax-5a interacts with the redox factor Ref-1,
indicating that there is the possibility for redox regulation of Pax-5a (Tell et al., 2000).
This was accomplished by treatment of cells with low doses of H 2O2 which resulted in
decreased Pax-5 DNA-binding activity. This suggests that Pax-5a functions most
efficiently in a reduced form (Tell et al., 2000). These data were supported by initial
studies done using recombinant Pax-5a and Pax - 8 paired domains that revealed evidence
for redox regulation though the conserved cysteine residues present in that region of the
protein (Tell et al., 1998). Thioredoxin (TRX) is a small 12kDa protein that also interacts
with Ref-1 as well as NF-icB/p50 (Hirota et al., 1999), which makes it a good candidate
for a role in redox regulation of Pax-5a, possibly by interactions with Pax-5e.
Our lab has hypothesized that the 27kDa Pax-5e complex is a heterodimer of Pax56 and TRX. This hypothesis is supported by immunoprecipitation experiments showing
that TRX coimmunoprecipitates with Pax-5e (Lowen et al., 2001). These samples were
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analyzed by western blot and probed with a catfish monoclonal anti-TRX (IgA) antibody.
The anti-TRX antibody also detected a 27kDa TRX-like species in LPS-activated small
resting B cells (SRB) nuclear extracts collected on day 0, 4, 6 , and

8

after activation.

More convincingly, the level of TRX increases over time with a peak at day 6 after LPS
activation and a slight decrease on day 8 , which corresponds to the expression pattern of
5e. Metabolically labeled LPS-activated small resting B cell (SRB) nuclear extracts from
day 2 and day 6 were immunoprecipitated with anti-Pax-5 antibody ED-1 serum,
6G11supernatant, or anti-TRX supernatants. A 27kDa complex is absent in day 2 nuclear
extracts but present on day 6 when immunoprecipitated with anti-Pax-5 (ED-1), anti-Pax5e (6G11), or anti-TRX antibodies. This provides strong evidence for the interaction of
Pax-5e with a TRX-like protein.
The role of each o f the Pax-5 isoforms remains under investigation. Pax-5e
appears to enhance the activity of Pax-5a in a dose-dependent manner (Lowen et al.,
2001). Transient transfection of the NIH3T3 cell line with a chloramphenicol
acetyltransferase (CAT) reporter construct (containing multiple Pax-5 a binding sites) as
well as with a Pax-5a and Pax-5e revealed that Pax-5a activity is enhanced, as shown by
an increase in percent CAT conversion. Proliferation experiments in cell lines have also
shown that increasing amounts of transfected Pax-5e in mature B cell lines A20/2J and
B17.10 lead to increased cell proliferation at earlier time points (Beth Jones, unpublished
data).
Based on these data, we hypothesize that Pax-5e regulates Pax-5a by increasing
Pax-5a activity. Pax-5e’s interaction with a protein such as thioredoxin suggests a
possible redox mechanism of Pax-5a regulation (Figure 1.4). Conceivably Pax-5e and 5a
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normally remain in an oxidized, or inactive, state. After stimulation of the B cell a
thioredoxin-like protein then interacts with and reduces Pax-5e, breaking existing
disulfide bonds. Once reduced, Pax-5e then induces reduction of Pax-5a which in turn
allows Pax-5 a to bind target gene promoters, resulting in expression or repression of
target genes. In this model, increasing amounts o f Pax-5e should lead to increased 5a
activity and thus increased expression or repression of target genes. In the case of genes
such as blk or c-myc, this may also cause increased proliferation of cells overexpressing
Pax-5e.

Research Questions
Based on the model proposed above, the objective of this thesis research was to
determine the effects on B cells of overexpressing alternative isoform Pax-5e in vivo,
using a murine model. While investigating these effects, several questions were
addressed. First, does Pax-5e increase the activity of Pax-5a leading to increased
proliferation of pro/pre-B, (im)mature B, and/or plasmablasts? Proliferation ELISAs
were used to detect a change in proliferation rate of cultured bone marrow or spleen cells.
LPS-activation of these cells was also used to determine which cell populations were
most affected. Secondly, will using flow cytometry reveal any changes in the size and
distribution of lymphoid populations such as pro/pre B cells, mature B cells or T cells in
the bone marrow or spleen? This analysis allowed determination of whether there are
increases in B cell populations that would indicate increased proliferation.
Finally, if overexpression of Pax-5e increases Pax-5a activity, are there changes
in Pax-5a target genes such as C D 19,J chain or blkl If target gene expression is altered,
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Model of Pax-5e activity in B cells
Cytoplasm
Pax-5e translocates TRX
into the nucleus; TRX
reduces Pax-5e
TRX/“F

Nucleus
Reduced Pax-5 e
binds to and
reduces oxidized
Pax-5 a

Figure 1.4: Model of possible interactions between Pax-5a, Pax-5e and thioredoxin
in B cells. As was proposed by Lowen et al. (2001), oxidized Pax-5e interacts with TRX
or undefined factor “F” (hatched octagon), inducing both a translocation of TRX/“F” into
the nucleus and reduction of Pax-5e. Reduced Pax-5e (square) can then interact with and
lead to the reduction of Pax-5a. Once reduced, Pax-5a (irregular shaded shape) is able to
bind DNA and initiate transcription of proliferation genes and other target genes. Pax-5e
reverts back to an oxidized state, exits the nucleus and is able to bind TRX again.
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how would this affect the mice when challenged by immunization? “Real time” PCR
was used as a tool in determining possible overexpression o f CD19 or blk, as well as
potential over-repression of J chain, using RNA extracted from spleen and bone marrow
cells in both immunized and non-immunized mice. In answering these questions, the in
vivo functions o f alterative isoform Pax-5 e have begun to be elucidated.

CHAPTER II
Methods and Materials
Transgenic Mice.

In collaboration with the University of Pennsylvania Transgenic

Mouse Facility, transgenic mice were developed that overexpress alternative isoform,
Pax-5e in a construct flanked by the murine H-2K promoter and the Ig-mu intronic
enhancer (Pircher et al., 1989) in a 6.0kb Xhol-Xhol fragment (ref) (see figure III. 1). The
transgenic mice (TG5e) were developed using a B 6 /SJL strain. The FI generation was
produced by crossing transgenic founders with wild-type SJL mice. Three-five
generations of mice were produced before separating negative and homozygous lines for
each strain. All mice were housed in semi-sterile conditions with sterilized food, water
and bedding.
DNA extraction. At 3 weeks of age, tail biopsies were collected and digested at 55°C for
16 hrs in 700pl of 50mM Tris (pH 8.0)/100mM EDTA/0.5% SDS and 35pl of Proteinase
K (lOmg/ml). DNA extraction was done using one phenol (equilibrated with Tris-HCl to
pH 8.0) and one phenol/chloroform extraction. DNA was precipitated for one hour in
1/10 of a volume of 3M sodium acetate (pH 6.0) and 2 volumes o f ethanol. Immediately
after precipitation, the samples were spun 30 seconds and pellets washed with 1ml of
70% ethanol, agitated briefly, and centrifuged for 1 minute. DNA pellets were
resuspended in lOOjul of TE (lOmM Tris-HCl (pH 8.0)/lmM EDTA). Optical densities
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were read using the Gene Quant II (Amersham Pharmacia Biotech) at 260nm.
Southern Blot. For each sample, 5pg of DNA was added to the appropriate volume of
sterile water to a final volume of 75pi 10 pi of 1.Omg/ml Bovine serum albumin, 10 pi
Bam HI buffer and 5pl Bam Rl restriction endonuclease were then added to each sample
and allowed to digest at 37°C overnight. After the digest, 10 pi of each sample was run
on a diagnostic 0.8% agarose gel to ensure proper digestion of the DNA. Samples were
then precipitated using 1/10 volume o f 3M sodium acetate (pH 6.0) and 2 volumes of
100% ethanol and incubated at -20°C for one hour. Following the incubation, the
samples were centrifuged for 25 minutes at 17,900 x g and the supernatants were
discarded. The samples were washed with 200pl of 70% ethanol and centrifuged for 5
minutes. The pellets were resuspended in 15pl TE plus 3pi of 6 X loading dye (25%
xylene cyanol, 25% bromophenol blue, 30% glycerol) and separated by gel
electrophoresis on a 0.8% agarose gel. A Polaroid photograph was taken of the gel after
ethidium bromide staining. The samples were transferred for 16 hrs onto a positively
charged nylon membrane (Roche) in an alkaline buffer (0.4M NaOH). After transfer, the
filter was rinsed in 2X SSC (20X stock= 3M NaCl, 300mM sodium citrate, pH 7.0) for 2
minutes then allowed to dry before UV cross-linking. Prehybridization in 5X
SSC/5XDenhardt’s solution/1% SDS/O.lmg/ml single-stranded Salmon testes DNA was
carried out at 65°C for 2 hours. The TG5e (Xhol-Xhol fragment, in Figure III. 1) probe
was created utilizing the Random Primed DNA Labeling Kit (Roche) according to
manufacturer’s instructions and using 5pl of 3000Ci/mmol o f [32P]a-labeled dCTP
(Amersham Pharmacia Biotech). The specific activity was > 5 x 108 CPM/pg. The
TG5e probe was added to the hybridization solution (same as the prehybridization) at a
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concentration of 1X106 CPM/ml and the membrane was incubated on a Little SHOT
Hybridization Oven (Boekel Scientific) for 16-24 hours at 65°C. After hybridizing, the
membrane was washed twice for 5 minutes in 2X SSC/0.1% SDS at room temperature,
twice for 5 minutes in 0.2X SSC/0.1% SDS at 42°C, and finally for 10 minutes in 0.1X
SSC/0.1% SDS at 65°C. The membrane was then exposed to a phosphor screen for 1
hour and read on the STORM 840 Phosphorimager (Amersham Pharmacia Biotech).
Band intensities were quantified using a STORM Scanner Control Version 5.01
(Molecular Dynamics, Inc.).
Polymerase Chain Reaction. Using DNA collected from the tail biopsies, 0. ljug DNA
was amplified over 35 cycles to determine if the mice contained the TG5e transgene.
Sense primer TG5e-l-S (5 ’-G AAGTT CT CAGGAT CCT CT AG AG-3 ’ covering a region
o f the MHC class I promoter ~70bp upstream from the of Pax-5e cDNA sequence - see
Figure III. 1) and anti-sense primer Pax-5d/kpn-AS (5’GACTGGTACCCTAGGACCCTGGG AAGCC-3’ covering nts 717-735 at the 3’ end of
Pax-5e) were used to amplify the TG5e transgene insert. This amplifies a 575nt fragment
which was visualized after ethidium bromide staining on a 2 % agarose gel.
RN A extraction and Northern Blot. Total RNA was extracted from spleen or thymus
using the Qiagen RNeasy Mini- or Midi-Prep according to the manufacturer’s
instructions. A total of 20jug of RNA was precipitated with 1pi of transfer RNA, 1/10
volume of RNase-free 3M sodium acetate (pH 6.0) and 2 volumes of ethanol for 16 hrs at
-20°C. The samples were centrifuged for 25 minutes at 4°C and 17,900x g and the
supernatant was discarded. Next, the samples were washed with lOOpl of 70% ethanol
and centrifuged for 5 minutes at 4°C and 17,900 x g. The pellets were resuspended in
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2.75|li1 diethyl pyrocarbonate (DEPC) treated water, 1.25pl 10X MOPS (0.4M MOPS,
0 .1M sodium acetate, 0.01M EDTA, and DEPC water to pH 7.0)/2.25jal 37%
formaldehyde, and 6.25pl formamide for a total volume of 12.5jlxL The samples were
then incubated for 15 minutes at 55°C followed by the addition of 2.5jul of RNA loading
dye (Im M EDTA [pH 8.0], 0.25% bromophenol blue, 0.25% xylene cyanol, 50%
glycerol) and loaded onto a 1% agarose gel containing IX MOPS and 6.7%
formaldehyde. The samples were separated by gel electrophoresis in a buffer of IX
MOPS. The gel was then stained with 0.5pg/ml o f ethidium bromide in 0.5M ammonium
acetate for 15 minutes and destained in DEPC water for 2 hours. The gel was viewed on
a UV transilluminator and a Polaroid photograph was taken of the gel to determine
relative sample concentrations. The gel was washed in 0.05M NaOH/1.5M NaCl for 15
minutes, then in 0.5M Tris/1.5M NaCl for 15 minutes and finally in 10X SSC for 15
minutes all at room temperature. The gel was transferred onto a positively charged
Roche nylon membrane according to manufacturer’s instructions and RNA allowed to
transfer for 16 hours in a solution o f 10XSSC. The membrane was then UV cross-linked
and prehybridized in a solution of 5X SSC, 5X Denhardt’s solution, 1% SDS, O.lmg/ml
denatured salmon testes DNA and DEPC water at 65°C for 2 hours. The hybridization
solution was the same as that for the prehybridization; however, lxlO 6 CPM/ml of 32Plabeled denatured TG5e probe was added to the mixture and the membrane was
incubated in a Little SHOT Hybridization Oven (Boekel Scientific) for 16-24 hours at
65°C. Following the hybridization, the membrane was washed twice for 5 minutes in 2X
SSC/0.1% SDS, twice for 5 minutes in 0.2X SSC/0.1% SDS (both at room temperature)
and finally for 15 minutes in 0.2X SSC/0.1% SDS at 42°C. The membrane was then
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exposed overnight to Kodak X-OMAT-AR film and developed on the Konica SRX-101
X-ray processor.
B and T cell Purification, B or T cells were purified from splenic cells using the SpinSep Murine B or T Cell Enrichment Kit (Stem Cell Technologies) according to the
manufacturer’s instructions. In brief, cells were purified via negative selection using
antibody cocktails against CD4, CD 8 , CD1 lb, TER119 and Ly-6 G (for B cell
purification) and CD1 lb, CD45R, TER119, and Ly-6 G (for T cell purification). Purified
B or T cells (at a yield of l-5 x l0 6 cells for each) were processed for RNA using the
RNeasy Mini Prep (Qiagen).
Reverse Transcriptase PCR. cDNA was prepared from RNA samples using the
Gene Amp RNA PCR kit (Applied Biosystems) according to the manufacturer’s
instructions and using 0.3jug RNA. Sense primers Pax-5-164-S (5’CCAGGCAGCTTCGGGTCA GCC-3’ covering nts 164-184 of Pax-5d) and Pdconl-S
(5 ’-ACCATGTTGCCTGGGAG-3 ’ covering nts 322-339 of Pax-5d and 5e) and Pax5d/kpn-AS (5’-GACTGGTACCCTAGGACCCTG GGAAGCC-3’ covering nts 717-735
of Pax-5d and 5e) were used to amplify the TG5e cDNA to determine expression of the
transgene. For Pax-5d, a 571nt fragment was amplified and for Pax-5d and 5e a 413nt
fragment was amplified.
Cell Purification and Culture. Spleen, bone marrow and thymus tissues were collected
from transgenic mice and negative littermate controls and disrupted in complete RPMI
medium (Fisher) using a 5ml syringe. Cells were forced through a 40jum nylon cell
strainer (Falcon) to create a single cell suspension then centrifuged for 10 minutes at 170
x g and 4°C. The supernatant was poured off and the cells were resuspended in 10ml
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HBSS (0.14M NaCl, 5.0mM KC1, 1.5mM Na 2H P 0 4 - 7H 20 , 5.5mM Dextrose, 20mM
Hepes, pH 7.05) and counted using a Brite-Line Hemacytometer (Hausser Scientific).
Cells to be used for ELISA or ELIspot were plated on 96-well tissue culture plates
(Coming) at 1X106 cells/well and incubated at 37°C in a C 0 2-Incubator (5.0% C 0 2).
Nuclear Extract Preparation. 500pl of lysis buffer (lOmM Hepes, pH 7.9, lOmM KC1,
0.1 mM EDTA, 0.4% Igepal [Sigma]) was added per 107cells and incubated for 15
minutes on ice. The samples were then centrifuged at 4°C, 17,900 x g for 1 minute.
Supernatants were saved as cytoplasmic fractions and frozen at -80°C. The remaining
nuclei were washed with 250pl of ice cold lysis buffer and centrifuged for 30 seconds.
The nuclear pellet was then resuspended in 250pl of ice cold extraction buffer (20mM
Hepes, pH 7.9, 0.4M NaCl, ImM EDTA) and agitated for 20 minutes at 4°C. The
samples were then centrifuged for 10 minutes at 17,900 x g and 4°C. Nuclear extract
aliquots were collected and stored at -80°C. All buffers contained the following mixture
o f protease inhibitors: ImM dithiothreitol, 0.5mM phenylmethylsulphonyl fluoride,
lOmg/ml aprotinin, 12.5mg/ml leupeptin, 1.25mg/ml pepstatin A, 0.5mg/ml trypsin
inhibitor). Protein concentrations were determined using the Bradford assay (Bio-Rad)
according to the manufacturer’s instmctions.
Western Blot. Nuclear extracts or whole cell lysates from tissues were resuspended in
complete 2X loading dye (50mM Tris-HCl, pH 6.8/5% 2-mercaptoethanol/10%
glycerol/1% SDS), separated on a 12% denaturing SDS/polyacrylamide gel and
electrophoretically transferred onto an Immuno-Blot PVDF Membrane (Bio-Rad) for 1
hour at 100V at 4°C. Following transfer, the membranes were incubated for 1 hour in
blocking solution (5% dry milk in PBS). The primary antibody, an anti-Pax-5 anti-semm
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called ED-1 (Zwollo et al., 1998), was added at 1:2000 in blocking solution to detect
Pax-5 a and -5e and incubated for 1 hour. The membranes were then washed 3 times for
10 minutes in PBS. A donkey anti-rabbit horseradish peroxidase-conjugated IgG
secondary antibody (Amersham Pharmacia Biotech) was added in blocking solution at
lpg/ml and incubated for 1 hour. The filters were then washed 3 times for 10 minutes in
PBS before developing with an enhanced chemiluminescence kit (ECL, Amersham
Pharmacia Biotech). The bands were detected on Kodak X-OMAT-AR film.
Flow Cytometry. Single cell suspensions were loaded onto 96-well round bottom plates
at

1 0 6 cells/well

and incubated with the antibody cocktail (0.5jag antibody/million cells of

each of three fluorescent antibodies in PBS) for 30 minutes on ice in the dark.
Fluorescent antibodies used were: CD45R/B220-PerCP, CD3-RPE, CD69-FITC, CD19RPE, IgM-FITC, CD43-RPE (all from BD Biosciences/Pharmingen). After incubation
the plates were centrifuged for 3 minutes at 1200rpm and the supernatants were discarded.
The cells were washed in 200pl of PBS and centrifuged for 3 minutes at 1200rpm and
supernatants were discarded. Each sample was resuspended in 200pl of PBS and
transferred to a 2.5ml flow cytometry tube. Samples were analyzed on the FACStarPlus
flow cytometer (Becton-Dickinson) using 50-70,000 events/sample.
Proliferation Assay. Spleen and bone marrow cells were plated on a 96-well flat bottom
plate at a concentration of 105 and 104 cells/well (in duplicate). Proliferation was
measured using the Cell Proliferation ELISA, BrdU Kit (Roche) according to the
manufacturer’s instructions. Briefly, lOjul of BrdU labeling solution was added to each
well and incubated for 18 hours in a CO 2 incubator (37°C and 5% CO 2). Cell
suspensions were then centrifuged for 10 minutes at lOOOrpm and the supernatants were
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discarded. Cells were dried using a standard hairdryer for 10 minutes then permeabilized
for 30 minutes at room temperature (using manufacturer’s reagents). After removal of
the fixing solution, an anti-BrdU-POD solution was added and incubated for 60 minutes
at room temperature. Cells were then rinsed and the substrate was added and allowed to
react for 2-5 minutes until a clear color change was observed. The reaction was stopped
using 1M H 2 SO4 and the optical densities (at 450nm) were obtained using a Microplate
Reader (Bio-Rad). Time points included: day 0, day 2 and day 3.
Immunizations. Transgenic mice and negative littermate controls were each immunized
intraperitoneally on day zero with 50jug of TNP-BSA in Freund’s Complete Adjuvant
(Sigma). On day 14, the mice each received a booster o f 50jLxg of TNP-BSA in Freund’s
Incomplete Adjuvant (Sigma). Blood was collected from the tail vein on day 21 and
allowed to clot for 4 hours at room temperature followed by an overnight incubation at
4°C. The blood clots were centrifuged for 10 minutes at 1700 x g and the serum was
collected for ELISA. The mice were euthanized on day 23 and spleen, bone marrow and
thymus collected for analysis.
ELISA. Cell samples were cultured in quadruplicate in complete RPMI medium on 96well plates, at

106

cells/well for 24 hours at 37°C in a CO 2 incubator (5.0% CO2 ).

Supernatants were collected and pooled for each sample and frozen at -20°C until needed.
96-well PRO-BIND Flat-bottom Assay Plates (Falcon) were coated with PBS containing
0.05% sodium azide and either lpg/m l TNP-LPS, anti-mouse IgM, or anti-mouse IgG for
24 hours at 4°C. After incubation, the plates were washed three times with ddE^O and
incubated for 1 hour with 250pl/well of blocking buffer (0.05% Tween 20, ImM EDTA,
0.25% BSA, 0.05% NaN3, 0.015M Na 2B 4O 7- 1 0 H2O and 0.12M NaCl, pH 8.0). The
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plates were then rinsed 3 times in ddHiO and samples (serum or supernatants) were
added in duplicate to the plate in dilutions of 1:4, 1:16 and 1:64 and incubated for 2 hours
at room temperature. The plates were then rinsed 3 times with ddH 2 0 and lOOpl of
horseradish-peroxidase conjugated secondary antibody (goat anti-mouse IgG or goat anti
mouse IgM; Zymed) in blocking solution (at 2pg/ml) was added to each well and
incubated for 2 hours at room temperature. Finally the plates were rinsed 5 times in
ddFbO and 50j l i 1 of developer (4.8ml citrate buffer, 5pi 30% H 2O2, 200jul 1% 2,2’-azinobis[3-ethylbenz-thiazoline-6-sulfonic acid]) (Sigma) was added to each well. The optical
density (at 405nm) of each sample was read after 5 or 10 minutes using a Microplate
Reader (Bio-Rad).
ELISPOT. Immuno-Blot PVDF membranes (Bio-Rad) were coated with either lpg/ml
of murine IgM or IgG, or lOOpg/ml of TNP-LPS on a Biodot Apparatus (Bio-Rad) and
incubated at room temperature for 2 hours on a platform rocker. After removing the
excess fluid, the membranes were blocked with post coating buffer (0.15M NaCl, 50mM
Tris, ImM EDTA, 0.15M Sucrose, 40g Casein) and incubated on a platform rocker for 1
hour. Membranes were then washed 3 times for 5 minutes with 250pl PBS/well. Cells in
complete RPMI (10% FBS) were diluted in a 96-well plate in duplicates o f 105 and 104
cells/well for each sample then loaded onto a Bio-Dot apparatus (Bio-Rad). The samples
were then incubated for 4 hours at 37°C, 5% CO 2. After incubation, the apparatus was
disassembled and the membranes were washed for 1 minute (3 times) in PBS. On a
platform rocker, the membranes were incubated with post coating buffer for

1

hour then

rinsed 3 times for 5 minutes with PBS. Next, the membranes were incubated with
2

pg/ml goat anti-mouse secondary antibody conjugated horseradish peroxidase (either
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anti-IgM or -IgG ) in PBS for one hour. The membranes were then washed 3 times for 10
minutes in PBS before adding the AEC detection reagent (20ml of substrate buffer:
1.75ml glacial acetic acid, 5.73gNaOAc, sterile ddHhO [pH 5.0]; for lOOpl of substrate:
0.2g 3-amino-9-ethylcarbazole in 5ml dimethylformamide; 20jul of 30% H2O 2).
Membranes were incubated for 10-20 minutes or until a clear color change was visable.
The membranes were allowed to dry for 16 hrs in the dark on filter paper and the filters
were analyzed by CTL Cellular Technology, Ltd. Immunospot Analyzers.
Quantitative “Real Tim e” PCR, cDNA was prepared from splenic RNA samples using
the GeneAmp RNA PCR kit (Applied Biosystems) according to the manufacturer’s
instructions and using 0.3-0.5pg RNA. Approximately 15-25ng of cDNA was then
amplified in a multiplex fashion in iQ Super Mix (Bio-Rad) using primers for (3-Tubulin
[Tubb5-s-q (5’ AT CTTC AG ACC AGAC AACTT CGTT 3’) Tubb5-as-q (5’
CCTT GC AGGC AAT C AC AGCT 3’) Tubb5-PROBE (5’
/5HEX/TCCGCCTCCTTCCGCACCACATCC/3BHQ-1/ 3’)] and Ig J chain [Jchain-s-q
(5’ CCCGATTCTTGCTACCTTGACT 3’) Jchain-as-q (5’
ACCCTGGTTTCAAATTCATTAGCA 3’) Jchain-PROBE (5’ /56FAM/AGCCACTCACCATGCAGCTCGTTG/3BHQ-2/ 3’)] or P-Tubulin and CD19
[Cdl9-s-q (5’ AGTGTCCCTGGGTCCTATGG 3’) Cdl9-as-q (5’
AGGTT GG AGT CGTT CT CAT AGAAT 3 ’) Cdl9-PROBE (5’ /56FAM/CCCTCCTCGCTGTCTGGCTCTTCA/3BHQ-2/ 3’)]. Amplification occurred
using 15 sec denaturing at 95°C, 30 sec annealing at 60°C, and 1 min extension at 72°C
over 40 cycles using the iCycler (Bio-Rad). Threshold values of the experimental gene
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(CD 19 or J chain) were expressed as a ratio o f the experimental gene to p-Tubulin to
account for within-sample variation.
Statistics. A student’s T-test was performed for ELISA, ELISPOT, qRT-PCR and flow
cytometry data using a two-tailed method to determine significance. A value of 0.03 was
designated as the p value; samples below which would be considered significant.

CHAPTER III
Results
Generation and Expression Analysis of TG5e Mice. To investigate the in vivo role of
Pax-5e in B cell development and activation, we developed transgenic mice that
overexpress Pax-5e. A construct containing full length Pax-5e flanked by the murine H2K promoter and the Immunoglobulin HC intronic enhancer was cloned (Figure III. 1A),
and transgenic mice were generated in collaboration with the University of Pennsylvania
Transgenic Mouse Facility. This construct was known to be expressed exclusively in B
and/or T lymphocytes (Malek et al., 1998). One would expect the MHC-class 1 H-2K
promoter to be expressed in all cell types, however this is limited by the Ig HC intronic
enhancer which is restricted to expression in B lymphocytes. It is unclear as to why this
construct can be expressed in T cells (Malek et a., 1998).
Ten TG5e founder mice (TG5e-7, 31, 32, 35, 36, 40, 49, 51, 58 and 62) were
obtained, 2 of which died at the Univ. of Pennsylvania transgenic facility before shipping
(TG5e-36 and 58) by the age of 4 weeks. Founders TG5e-40, 32, 35 and 51 never
produced transgenic offspring, while founder 62 died o f unknown causes shortly before
delivering her first litter. Founder TG5e-31 successfully delivered one litter of transgenic
offspring yet died of squamous cell carcinoma before more offspring could be produced.
Thus, 40% of the TG5e transgenic founders died within 2 months of birth. The remaining
founders, TG5e-7 and TG5e-49, successfully bred with wild-type SJL females and
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A.
TG-5e transgenic construct
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Figure III.1A: TG5e Transgenic construct. The construct contains a copy of the Pax5e coding sequence flanked by the H2k-promoter and the Ig HC enhancer. This construct
was cloned into the pHSE3’ vector (a gift from Dr. Steve Desiderio).
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homozygous transgenics and negative littermate control lines were developed.
Analysis of tail biopsy DNA by PCR and Southern blot allowed us to determine
which mice were positive for the TG5e transgene. TG5e

or “+/+” mice of both

strains were determined through PCR amplification, yielding a 575bp DNA fragment,
while negative littermate controls

yielded no band (Figure III. IB). Results were

confirmed using southern blot analysis; TG5e mice yielded bands of approximately
4500bp that were absent in negative mice. Furthermore, using Southern blots,
homozygous transgenics yielded bands of approximately twice the intensity of known
heterozygotes (Figure III. 1C), as determined using Phosphorimager analysis.
Expression of the TG5e transgene was examined at the RNA transcript level using
both reverse transcriptase PCR (RT-PCR) and northern blot. Using RNA from the spleen,
TG5e mice showed a PCR product of 413bp and a specific band on the northern blot; a
band which represents both the transgenic and endogenous Pax-5e transcripts (Figure
III.2A). The transgenic pHSE3’ construct has previously been used for overexpression of
T cell receptor and blk genes and has been shown to be expressed in B and/or T cell
lineages (Malek et al., 1998). To determine which lymphocyte population was
expressing TG5e, we purified B or T cell populations from spleen or thymus o f each
founder line. Total RNA was extracted from each of the two lymphoid cell fractions, and
analyzed via RT-PCR. TG5e-7 offspring expressed TG5e in B cells only, lacking any
bands in samples containing T cell cDNA, while TG5e-49 offspring expressed TG5e in
both B and T cell populations (Figure III.2B). Negative littermate controls showed a very
faint band representing endogenous Pax-5e transcripts; however, at a much lower
intensity than the transgenics (Figure III.2B).
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Figure III.1B and III.1C: Screening of founder TG5e founder progeny for genomic
incorporation of the TG5e DNA construct. Tail biopsy DNA from TG5e offspring was
analyzed for the presence of the TG5e construct. (B.) The samples were evaluated by
PCR revealing a band of 575bp if the mouse was positive for the transgene (lanes 1 and 2)
and no band if the mouse was negative (lanes 3 and 4). The negative control was in lane
5 while positive control o f pcDNA.5e was used to indicate the size of the TG5e band in
lane 6 . Size marker XHindlll was used in lane 7. (C.) Southern blot analysis was used to
confirm PCR results, as well as to quantify the amount of TG5e present in the sample to
determine if the mouse was homozygous, heterozygous or negative. Lane 1 is negative,
lanes 2, 3 and 5 are heterozygous and lane 4 is homozygous for TG5e. The values for
percent band intensity were based on background intensity and acquired from
Phosphorimager analysis.

37

J3-tubulin

B.

T cells
“+/+”

B cells
“+/+”

Controls
5e

5d
Pax-5d
TG5e/endo
genous 5e

Pax-5d
TG5e/endo
genous 5e

Figure UI.2A and IIL2B: Analysis of TG5e transcripts in TG5e-7 and -49 progeny.
Total RNA was extracted from spleen or thymus tissue and analyzed via northern blot to
verify expression of the TG5e transgene in positive mice in (A.) Spleen RNA from
TG5e-49 and negative progeny (a representative experiment is shown). Lanes in the
northern blot are as follows for both panels: lane 1 negative control, lane 2 heterozygous
control, lanes 3-5 homozygous progeny, lanes 6 - 8 negative progeny. The lower panel
represents a P-tubulin control indicating total RNA concentrations in each lane. (B). RTPCR analysis of purified B and T cell populations from each strain (TG5e-7 upper panel,
TG5e-49 lower panel). Lane 1 represents
T cell, lane 2 “+/+” T cell, lane 3
B
cell, lane 4 “+/+” B cell and lane 5 and 6 are controls samples pcDNA.5e and ,5d,
respectively.
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Splenic nuclear extracts from both homozygous and negative littermate controls
of TG5e-7 and -49 overexpression of Pax-5e protein was analyzed in western blot. Blots
were probed with anti-Pax-5d/5e monoclonal antibody 6G11 (Anspach et al., 2001).
Both transgenic and negative mice yielded a band of 19kDa, characteristic of the
endogenous Pax-5e protein (Lowen et al., 2001). However, homozygous mice o f TG5e-7
(Figure III.2C) and TG5e-49 (Figure III.2D) revealed bands of greater intensity
indicating overexpression due to the transgene. Since RT-PCR had shown TG5e to be
expressed in the T cells of strain TG5e-49, we also analyzed nuclear extracts from the
thymus of that strain (Figure III.2E). Due to the presence of a 19kDa band on the
western, we concluded that the Pax-5e protein is also overexpressed in the thymus of
TG5e-49. Pax-5e has also been reported to run at 27kDa. This slower mobility band is
hypothesized to be a heterodimer of Pax-5e with a thioredoxin-like molecule (Lowen et
al., 2001). Due to variation between experiments, the 27kDa band shows no consistent
pattern. Overexpression of Pax-5e was then confirmed in all blots by probing with a
control anti-TFIID antibody, which was expressed equally in all samples.

Analysis of Lymphocyte Populations. To determine if overexpression of Pax-5e
affected size and distribution of lymphoid populations, splenic or bone marrow cells were
collected from

6

week old homozygous and negative littermate controls from each strain

and analyzed via flow cytometry (Figure III.3A and 3B). Using markers PerCPconjugated B220 (CD45R), PE-conjugated CD 19 and FITC-conjugated IgM, as well as
the progenitor marker PE-conjugated CD43, we identified specific B cell subpopulations
within the spleen and bone marrow (Table III. 1).
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Pax-5e (19kD)

TFIID

Figure IIL2C: TG5e protein expression in TG5e-7. Splenic nuclear extracts were
prepared for TG5e-7 with age matched littermate controls and separated by SDS-PAGE
then transferred to a PVDF membrane for western blotting. The blot was probed with
novel-sequence (Pax-5d/5e) specific 6G11 antibody. Overexpression of Pax-5e in TG5e7 progeny (“+/+”) is shown. Anti-TFIID antibody was used to indicate the amount of
total protein in each sample.
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Figure III.2D and III.2E: TG5e protein expression in TG5e-49. Nuclear extracts
were prepared for TG5e-49 with age matched littermate controls and separated by SDSPAGE then transferred to a PVDF membrane for western blotting. The blot was probed
with novel-sequence specific 6G11 antibody. (D.) Analysis of spleen nuclear extracts
reveals overexpression of Pax-5e in TG5e-49, while (E.) shows the same overexpression
in the thymus. Anti-TFIID antibody was used in each experiment to determine the
amount of total protein in each sample.
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B cells----------------------------------- — T cells—
Cell surface
marker
B220
CD43
CD19
IgM
CD3

Pro-B
early Pre-B
+
+
-/+

All
T cells

Late Pre-B
(Im)mature B
+

Plasmablast
+/-

Plasma
Cell
-

-

-

-

-

-

+/+/-

-

-

-

+
+

-

-

-

-

-

-

+

Table III.1: Flow cytometry markers. Shown above is a list of cell surface markers
used to differentiate different lymphoid populations. (+) indicates the marker is present
at that stage/cell type, (-) indicates the absence of the marker.
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For the TG5e-7 progeny we acquired data from a total of 7 transgenic and 7
negative age-matched mice used over 3 independent experiments. TG5e-7 progeny
exhibited no consistent changes in any lymphoid populations in the spleen or in the bone
marrow as compared to negative littermate controls (Figure III.3A). In the first
experiment we saw a decrease in B220+ cells in the transgenics; however, the second
experiment revealed the opposite trend, and the third showed no change. This pattern
was also seen in CD3+ cells, leading us to the following two conclusions: 1) there is
considerable variation in lymphoid populations in TG5e-7 and 2) there are no significant
changes in lymphocyte populations in TG5e-7 progeny.
Analysis of TG5e-49, with a total of 9 transgenic and 9 negative mice used over 3
independent experiments, revealed decreases in CD3+ T cells. First, TG5e-49 progeny
showed a significant decrease in CD3+ T cells (CD3+B220-) in the bone marrow
(p=0.015<0.03) (a representative experiment is shown in Figure III.3B). Negative
littermate controls contained an average of 3.7% T cells in the bone marrow while TG5e49 mice only showed an average of 2.2% T cells in the same tissue; a decrease of 41%.
This significant decrease in CD3+ T cells was also apparent in the spleen (p=0.017<0.03).
Splenic CD3+ T cells (CD3+B220-) comprised an average of 36% o f non-transgenic
mouse lymphoid populations; however, TG5e-49 mice showed only 30.2%; a decrease of
16.7%. This provides evidence that, when expressed, Pax-5e can affect the development,
proliferation or apoptosis rate in T cells. No significant change was observed within any
thymic cell population. In the bone marrow there was a slight decrease in pro-B cells
(B220+CD43+); however, these data were not significant as only 5 out of 9 TG5e-49
progeny exhibited this phenotype (p=0.36>0.03).
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50.7%

CD43
11.2 %

B220

Figure III.3A: Analysis of lymphoid populations for TG5e-7 progeny using flow
cytometry. Spleen and bone marrow of 6 week old transgenics and negative littermate
controls were collected and analyzed via double staining with the combinations
illustrated above. TG5e-7: top panels include PE-CD3 (T cells) vs. PerCP-B220 (B cells)
for the spleens of both negative and transgenic mice. The lower panel contains
representative samples from the bone marrow comparing PerCP-B220 (x-axis) against
PE-CD3 (middle) or PE-CD43 (progenitors, bottom). Percent gated cells are labeled in
each quadrant.
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CD43

Figure III.3B: Analysis of lymphoid populations for TG5e-49 progeny using flow
cytometry. Spleen and bone marrow of 6 week old transgenics and negative littermate
controls were collected and analyzed via double staining with the combinations
illustrated above. TG5e-49: top panels include PE-CD3 (T cells) vs. PerCP-B220 (B
cells) for the spleens of both negative and transgenic mice. The lower panel contains
representative samples from the bone marrow comparing PerCP-B220 (x-axis) against
PE-CD3 (middle) or PE-CD43 (progenitor cells, bottom). Percent gated cells are shown
for each quadrant.
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In summary, TG5e-7 progeny showed no significant changes in any lymphoid
populations in non-immunized mice. On the other hand, TG5e-49 progeny showed
decreases in CD3+ T cell in both the spleen and bone marrow but not in the thymus.
Frequencies of B cell populations in either strain were unaffected by the transgene.

Effects of TG5e on cell proliferation in culture. As indicated by previous research,
overexpression of Pax-5a leads to increased B cell proliferation (Max et al., 1995). Our
lab had also demonstrated that: 1) isoform Pax-5e can enhance the activity of Pax-5a in
mature B cell lines (Lowen et al., 2001), and 2) ectopically expressed Pax-5e can increase
cell growth in B cell lines (Beth Jones, unpublished data). Therefore, we decided to
examine the effects of B (and T) lymphocyte proliferation in the TG5e mice as compared
to negative littermate controls. Cultured bone marrow and resting B and T lymphocytes
(70% Percoll separated) from both strains were grown in the presence or absence of
lipopolysaccharide (LPS). This mitogen stimulates B cell activation and proliferation as
well as differentiation into plasma cells. Proliferation was measured through BrdU
incorporation and was analyzed via a colorimetric proliferation ELISA (Roche).
Freshly isolated, unstimulated bone marrow cells of TG5e-7 progeny exhibited a
25% increase in proliferation on day 0, as compared to negative littermate controls
(p=0.0001<0.03) (Figure III.4A). We also recorded proliferation on day 2 and 3 for
unstimulated bone marrow cells. Interestingly, no difference was observed between
transgenic and negative mice on day 2 (p=0.13>0.03), but a 43% decrease in proliferation
in TG5e-7 cells was detected on day 3 (p=0.0008<0.03) (Figure III.4A). Unstimulated,
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resting mature splenocytes (“70%”) showed no significant change in proliferation state
on day 0 (p=0.09>0.03) (data not shown), although significant variation was observed.
LPS-activated bone marrow cells of TG5e-7 progeny showed no significant
change in proliferation on day 3, as compared to negative littermate controls
(p=0.39>0.03). Also on day 3, LPS-activated TG5e-7 splenic cells revealed no
significant change in proliferation (p=0.17>0.03) (Figure III.4B).
In summary, TG5e-7 bone marrow cells exhibit an increase in proliferation
without LPS stimulation on day 0, and then show a significant decrease in proliferation
after 3 days. On day 0, neither stimulated bone marrow cells nor unstimulated spleen
cells displayed a significant change in proliferation as compared to negative littermate
controls. Finally, stimulated spleen cells revealed no change in proliferation rate after
LPS induction on day 3.
TG5e-49 progeny exhibited no significant change in proliferation in unstimulated
bone marrow cells on day 0 (p=0.5>0.03) (Figure III.4C). However, on day 3,
unstimulated bone marrow cells demonstrated a 19.5% increase in proliferation
(p=0.01<0.03) (Figure III.4C). Unstimulated splenic cells displayed no significant
change in proliferation as compared to negative littermate controls on day 0
(p=0.45>0.03) (data not shown). Stimulation of bone marrow cells with LPS for 3 days
revealed a 21% increase in proliferation rate for the TG5e-49 mice compared to negative
controls (p=0.019<0.03) (Figure III.4D). LPS-activated TG5e-49 splenic cells showed
no significant change in proliferation (p=0.04>0.03) (Figure III.4D).
In summary, the presence of the transgene in TG5e-49 results in a significant
increase in proliferation for both stimulated and unstimulated bone marrow cells on day 3.

47

A.
TG5e-7 Unstim ulated Bone M arrow Cell Proliferation

B.
TG5e-7 LPS-Activated
Bone M arrow Cell Proliferation
Spleen Cell Proliferation
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Figure IIL4A and III.4B: Effect of TG5e on bone m arrow and spleen cell
proliferation in TG5e-7. Unstimulated bone marrow cells were diluted to 105 cells/well
and incubated with BrdU for 18 hours before colorimetric analysis of BrdU incorporation
with experiments spanning (A.) day 0, 2 and 3 for unstimulated bone marrow cells and (B)
3 days after LPS-activation of bone marrow or spleen cells. Measurements were read by a
Microplate Reader (Bio-Rad). Relative proliferation rate of the negative littermate
controls were set at 1 0 0 % and the transgenics were indicated as a percent change in
proliferation, N=9 over 3 independent experiments (* represents p value< 0.03).
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Figure III.4C and III.4D: Effect of TG5e on bone m arrow and spleen cell
proliferation in TG5e-49. Unstimulated cells were diluted to 105 cells/well and
incubated with BrdU for 18 hours before colorimetric analysis of BrdU incorporation
with experiments spanning (C.) day 0 and day 3 for unstimulated bone marrow cells and
(B) 3 days after LPS-activation of bone marrow or spleen cells. As in previous figure,
the negative controls represent 100%, N=9 over 3 independent experiments (* represents
p value< 0.03).
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However, no change in proliferation was seen in either unstimulated spleen or bone
marrow cells on day 0, nor was a change in proliferation evident in LPS-activated spleen
cells on day 3.

Changes in Ig secretion in immunized TG5e mice. TG5e offspring from both strains
and age-matched littermate controls were immunized with TNP-conjugated Bovine
Serum Albumin (BSA) in order to examine the effects of the TG5e-transgene on the
immune response. Supernatants from splenic, bone marrow and thymic cells were
analyzed for both TNP-specific and total IgG and IgM levels by ELISA. Additionally,
live cells were cultured on immunoblot membranes coated with anti-IgM or -IgG
antibodies to determine the number o f Ig-secreting cells by the ELISPOT technique.
After 24hours in culture, supernatants from 106 spleen or bone marrow cells were
collected and diluted 1:4 and 1:16 for analysis by ELISA. Standards ranging from
1000ng-0. lng o f IgG (or IgM) were also plated in order to generate a standard curve and
to evaluate actual Ig concentrations of each sample. TG5e-7 progeny showed a
significant increase in total IgM and IgG levels in the spleen (Figure III.5A). The
transgenic mice produced an average of 7800ng IgG/106 cells, an increase of 43.6% over
the negative littermate control average of4400ng IgG/106 cells (p=0.01<0.03). Total
IgM for TG5e-7 also showed a significant increase over the negative mice. TG5e-7 mice
generated almost 2000ng IgM/106 cells versus only 1500ng IgM/106 cells from the
negative mice, a difference of 25% (p=0.01<0.03). Total IgM produced in the bone
marrow showed no significant change (p=0.09>0.03) (Figure III.5A). Total IgG
originating in the bone marrow showed no change compared to negative littermate
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controls (data not shown). IgG antibodies specific to the hapten carrier TNP were also
analyzed for both tissues; however, values were too low to be considered reliable.
Samples from TG5e-49 were analyzed under conditions identical to those of
TG5e-7, but were also evaluated for antibody production from thymic B cells. TG5e-49
progeny revealed a 46.8% decrease in total splenic IgG (p=0.004<0.03); decreasing from
1400ng IgG/106 cells to 750ng IgG/106 cells (Figure III.5B). Conversely, no change was
found in splenic IgM (p=0.5>0.03); however, in the bone marrow TG5e-49 mice
displayed a 63.4% decrease in total IgM; a drop from 142 to 52ng IgM/106 cells
(p=0.004<0.03) (Figure III.5B). Furthermore, no changes were observed in bone marrow
IgG and, as with TG5e-7, the level of TNP-specific IgG in the bone marrow or spleen
was too low for measurement (data not shown). Concentrations of both IgM and IgG
found in the thymus were also measured; however, the transgenics showed no significant
change over negative control mice (data not shown).
To determine whether changes observed in secreted antibody levels were due to
altered plasmablast/plasma cell populations, we performed ELISPOT. Using a dot-blot
apparatus containing membranes coated with IgM, IgG or TNP-KLH, dilutions of 106 or
105 cells were plated and allowed to secrete Ig on the membranes for 4 hours. After
washing, the IgM membranes were probed with goat anti-mouse IgM-HRP while the
TNP-KLH and IgG membranes were probed with goat anti-mouse IgG-HRP. The
membranes were then shipped to Cellular Technologies Ltd. where the number and size
o f spots in each well were analyzed by computer-based software.
TG5e-7 progeny show significant increases of 2 and 3 fold for spleen (p=0.006)
and bone marrow (p=0.004<0.03) for total IgG-secreting cells, respectively (Figure
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Figure III.5A and III.5B: The effects of TG5e on Ig-secretion in the spleen and bone
m arrow . Spleen and bone marrow cells o f A) TG5e-7 and B) TG5e-49 and negative
mice were collected and grown in culture for 24hrs. Supernatants were analyzed by
ELISA against a set of standards of known Ig concentration for the presence of total IgM
or IgG. Spleen IgM and IgG and bone marrow IgM levels are shown. N=7 over 2
independent experiments (* represents p<0.03).
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III.6 A & B). Transgenics also show a significant 3-fold increase in the number of TNPspecific IgG-producing cells in the bone marrow (p=0.0 160.03); however, no significant
trend was seen in the spleen (p=0.04>0.03) as there was too much variation within counts
from both dilutions (data not shown). Membranes analyzed for changes for IgMsecreting cells also showed a significant increase in cell numbers in the spleen as
compared to negative control mice (p=0.0000020.03) (Figure III.6 A). No significant
changes were observed in the bone marrow (p O .0 8 0 .0 3 ) (data not shown). We
conclude that TG5e plays a role in increasing the number of Ig-secreting cells in the bone
marrow and spleen from immunized transgenic mice.
Similar trends were seen in TG5e-49 progeny although none of the changes were
significant for total number of IgG-secreting cells in the spleen (p O .7 0 .0 3 ) or bone
marrow (p= 0.30.03) (Figure III.6 C and III.6 D). There were also no changes in the
number of TNP-specific IgG-secreting cells in the bone marrow (pO .6O .03), while the
number of TNP-specific IgG-secreting cells in the spleen increased significantly by 5fold over the negative control mice (p=0.015<0.03). Due to limited resources, we were
unable to analyze changes in IgM-secreting cells for this strain.

Changes in lymphoid populations in transgenic mice after immunization using flow
cytometry. Following immunization of transgenics from both strains and negative
littermate controls, 2 x l 0 6 cells were stained with the same fluorescent antibodies used for
non-immunized mice then fixed in 2% paraformaldehyde until needed. Cells were then
thawed at 37°C and analyzed by flow cytometry. We analyzed spleen and bone marrow
for TG5e-7 and TG5e-49, as well as thymus for TG5e-49.
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Figure IH.6 A and III. 6 B: Effects of TG5e on the num ber of IgG-secreting cells in
TG5e-7 as determ ined by ELISPOT. Bone marrow and spleen cells from TG5e-7 were
cultured on membranes coated with TNP-KLH or IgG on a dot-blot apparatus (Bio-Rad)
separately in dilutions of 106 cells/well. Membranes were probed with goat anti-mouse
IgG-HRP and sent to Cellular Technologies Ltd. for computer-based counting of spots.
These data allowed for more accurate determination o f total number of IgG-secreting
cells or TNP-specific IgG-secreting cells present in the tissue, N = 8 (4 mice done in
duplicate) (* represents p value<0.03, all others p>0.03).
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Figure IIL 6 C and III. 6 D: Effects of TG5e on the num ber of IgG-secreting cells in
TG5e-49 as determ ined by ELISPOT. Bone marrow and spleen cells from TG5e-49
were cultured and probed as described in Figures III.6 A and III.6 B, N = 6 (3 mice done in
duplicate) (* represents p value<0.03, all others p>0.03).
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After acquiring 70,000 events (or number of cells), all TG5e-7 progeny revealed
significant increases in pre-B and (im)mature B cells (B220+CD19+) (p=0.007<0.03) and
in (im)mature B cells (B220+IgM+) (N= 8 , p=0.002<0.03) in the bone marrow (Figure
III.7A). The total number of B220+CD19+ cells in the transgenics increased an average
o f 18.7% over a total of 4 negative littermate controls and similarly, a 21% increase was
seen in B220+IgM+ cells in the transgenics. This suggests that TG5e has some effect on
immature and mature B cell stages in the bone marrow, and maybe pre-B cells as well,
possibly causing excess proliferation during an immune response. No effects were seen
in the T cell populations or progenitor cell populations in the bone marrow.
Unfortunately, the fixation process adversely affected the condition of the spleen cell
samples and thus we were unable to obtain reliable counts.
TG5e-49 displayed a strikingly different phenotype after immunization as
compared to pre-immunization. There was a significant decrease in B220+CD3- cells (B
cells) in the spleen (p=0.027<0.03) by 33.1% over the negative control mice (Figure
III.7B). There was also a 34.8% decreases in CD3+ T cells in the spleen (p=0.006<0.03)
(Figure III.7B). Though there was a slight decreases in CD3+ T cells in the thymus, this
was not significant (p=0.05>0.03) (data not shown). Within the splenic B cell
populations we found a significant decrease of 21.3% in IgM+CD19+ B cells
(p=0.007<0.03). This decrease suggests that during an immune response, overexpression
Pax-5e leads to increased (im)mature B cell death. The bone marrow of TG5e-49
displayed a 46.5% increase in progenitor B cells (B220+CD43+) (Figure III.7B). During
an immune response, the bone marrow increases immune cell production so proliferation
is to be expected. Regarding the TG5e-49 mice, it is possible that overexpression of Pax-
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B220

Figure IIL7A: Changes in lymphoid populations in TG5e-7 after immunization.
Analysis of bone marrow from 10 week old immunized transgenics and negative
littermate controls after double staining with PE-CD19/PerCP-B220 (top panel) or FITCIgM/PerCP-B220 (middle panel) or PE-CD3/ PerCP-B220 (bottom panel) are shown
above. Percent gated cells are shown for each quadrant.
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Figure HI.7B: Changes in lymphoid populations in TG5e-49 after immunization.
Analysis o f bone marrow and spleen tissues from 10 week old immunized transgenics
and negative littermate controls after double staining with FITC-IgM/PE-CD19
(mature/immature B cells, top panel) or PerCP-B220/PE-CD3 (B/T cells respectively,
middle panel) or PE-CD43 (progenitor cells, bottom panel) are shown above. Percent
gated cells are shown for each quadrant (one experiment, N= 6 ).
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5e is leading to increased cell proliferation in early B and T cell stages by enhancing the
effect of Pax-5a on target proliferation genes (e.g. blk).

Analysis of Pax-5a target gene expression. Since our previous data support the
hypothesis that Pax-5e enhances Pax-5a activity (Lowen et al., 2001; Beth Jones,
unpublished data), we wished to test if Pax-5a target genes were affected by the
overexpression of Pax-5e. Using quantitative “real-time” PCR (qRT-PCR) we analyzed
the transgenic mice o f both strains for any change in the expression of Pax-5a target
genes CD 19 and immunoglobulin joining chain (J chain) in the spleen. Target gene
expression was investigated in both immunized and non-immunized transgenics and
negative littermate controls.
Analysis of 3 age-matched transgenics and 3 negative littermate controls from
non-immunized TG5e-7 displayed no significant changes in CD19 (p=0.2>0.03) or J
chain (p=0.3>0.03) expression (data not shown). Similarly with TG5e-49, nonimmunized transgenic mice showed no consistent changes in expression of either CD 19
(p=0.9>0.03) or J chain (0.7>0.03) (data not shown). For each strain, 3 independent
experiments were run. The data were combined and shown as the negative mice
representing

1 0 0 %,

while the transgenics represent a percent change from their negative

littermate controls. Based on these data, we conclude that TG5e does not affect the
expression of J chain or CD 19 in non-immunized transgenic mice.
RNA samples from the spleens of immunized TG5e-7 and 49 progeny were also
collected and processed via qRT-PCR. Immunized TG5e-7 progeny revealed no
significant change in CD 19 (p=0.2>0.03) or J chain (p=0.7>0.03) expression (Figure
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III.8 A). Whereas, a significant increase in CD19 expression in TG5e-49 (p=0.022<0.03)
was apparent. This increase in expression was 20% over the negative control mice. No
change was observed in the expression o f J chain of the same mice (p=0.65>0.03) (Figure
III.8 B). These results suggest that immunization of TG5e-49 mice has no effect on the
expression of J chain but leads to the increased expression of CD 19. At the same time,
immunized TG5e-7 mice show no significant change from the unimmunized state.
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Figure III. 8 A and III. 8 B: Changes in Pax-5a target genes CD19 and J chain in
immunized transgenic mice. Total RNA was extracted from the spleens of immunized
A). TG5e-7 and B). TG5e-9 offspring and negative littermate controls and cDNA was
analyzed via quantitative “real time” PCR for changes in CD 19 and J chain expression.
(3-Tubulin was used as an internal control. The values were calculated by normalizing
the
to 100% based on the inverse ratio of the threshold value (Ct) of the target gene
to the Ct of the control gene. Values for 3 independent experiments, N=9, * represents
p<0.03.

CHAPTER IV
Discussion
The transcription factor Pax-5a is a master regulator o f B cell development and
proliferation. In this thesis research, we generated transgenic mice overexpressing
alternative isoform Pax-5e and acquired two founder mice: TG5e-7 and TG5e-49. RTPCR revealed that TG5e-7 mice expressed the transgene in only the B cells, while TG5e49 expressed in both B and T cells. We found an increase in cell proliferation in the bone
marrow of both strains. After immunization, TG5e-7 mice showed an increase in the
number of antibody-secreting cells as well as an increase in the total amount of secreted
IgG and IgM. ELISPOT analysis o f TG5e-49 showed no change in the numbers of
antibody-secreting cells, but a shift towards smaller ELISPOTs, indicating more
plasmablasts and less plasma cells. These mice also showed a decrease in IgG levels.
Flow cytometry of immunized mice revealed increases in pre, immature and mature B
cells in TG5e-7 in the bone marrow whereas TG5e-49 showed decreases in the same B
cell stages as well as decreases in T cell populations. Finally, “real time” PCR indicated
overexpression of CD19 in TG5e-49 mice but not in TG5e-7 mice.
Based on this data, the two transgenic lines display distinct phenotypes although
overlapping for bone marrow proliferation. Several conclusions can be drawn from the
data collected from the transgenic mice relating to B cell proliferation and changes in
Pax-5a target gene expression. This murine model allows us to further investigate the
role of Pax-5e.
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TG5e affects lymphocyte proliferation
TG5e-7 bone marrow cells undergo increased proliferation. Previous results in our
lab have shown that overexpression of Pax-5e in vitro leads to increased cell proliferation
(Lowen et al., 2001). Based on these data, we hypothesized that increased levels o f Pax5e protein in vivo would also lead to increased cell proliferation in both the spleen and
bone marrow. By utilizing a proliferation ELISA, we were able to determine the
proliferation rates of spleen and bone marrow cells from TG5e-7. Unstimulated, fresh
bone marrow cells from TG5e-7 mice showed a significant increase in proliferation on
day 0 compared to control mice. This supports our hypothesis that overexpression of
Pax-5e will increase cell proliferation. This increase in proliferation was not seen on day
2. Then, on day 3, these cells displayed a significant decrease in proliferation as
compared to negative littermate controls. This decrease in proliferation was not predicted
by our hypothesis, but is discussed in more detail in the next section.
We know that TG5e-7 expresses the transgene in the B cells; however, we do not
know in which B cell population this increase in proliferation is occurring. The H2K
promoter/immunoglobulin HC enhancer combination in the TG5e construct is known to
be active at early stages of lymphocyte development (Pircher et al., 1989), including the
pro- and/or pre-B cell stages. Normally, during early stages of lymphocyte development
in the bone marrow, hematopoietic stem cells and lymphoid progenitors undergo a form
o f regulated proliferation in order to expand pro- and pre-B cell populations. It is
possible that overexpression of Pax-5e in B cells during normal proliferation events leads
to increased proliferation rates. Normal proliferation of B cells occurs after checkpoints
which ensure the IgH and IgL genes are properly rearranged (Hardy et al., 1991). Pro-
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and pre-B cells that have successfully rearranged their IgH gene and express a complete
pre-BCR (or after IgL rearrangement, a BCR), will continue to proliferate and carry on to
the next stage of B cell development. If Pax-5e enhances the activity of Pax-5a, which
regulates these stage-specific proliferation events, this may explain why there is increased
proliferation in the bone marrow of the transgenic mice.
Pax-5a is involved in activating the expression of the pre-BCR of the pre-B cell,
thus overexpression of Pax-5e may lead to increased production of the pre-BCR
components. Pax-5a binding sites are found on pre-BCR components VpreB and X5 of
the surrogate light chain (Tian et al., 1997). Pax-5a is also known to regulate the
expression of k sterile transcripts during the rearrangement of the IgK gene (part of the
IgL chain) and in the absence of sterile transcript production, the IgK gene will not
rearrange (Sato et al., 2004). Thus, Pax-5a is essential for producing a properly formed
pre-BCR. Furthermore, studies utilizing transgenic mice that express Pax-5a in
thymocytes have shown that Pax-5a is sufficient to induce V-DJ rearrangement of the
IgH locus in pre-T cells (CD4+CD8+) (Hsu et al., 2004). With this in mind,
overexpression of Pax-5e may not only enhance the activity of Pax-5a resulting in
overexpression of proliferation genes like blk, but also increase the rate of IgH locus
rearrangement as well as increased sterile k transcript production or VpreB/A.5 expression,
boosting pre-BCR assembly. This could lead to increased proliferation through a more
rapid production of pre-BCRs, allowing cells to pass checkpoints more quickly and thus
reaching the next stage of development sooner. If cells mature quickly, this may
contribute to the increased pre/immature/mature B cell numbers seen in immunized
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TG5e-7. Early stage B cells proliferate and mature more rapidly in transgenic mice;
therefore more B cells are available for activation by immunization.

Do TG5e-7 bone marrow cells undergo increased apoptosis as a result of increased
proliferation? The increased proliferation seen on day 0 in freshly isolated TG5e-7 bone
marrow cells most likely indicates what is actually going on in the bone marrow in vivo.
On the other hand, after day 3 in culture growth in vitro, TG5e-7 bone marrow cells
showed a significant decrease in proliferation compared to those from wild-type mice.
Though this decrease in proliferation may not be indicative of actual in vivo events, it is
important to note that the cells o f the transgenic mice behave dramatically different than
the wild-type mice. This drop in proliferation could indicate that the cells are unable to
sustain such rapid growth in culture or that apoptosis is induced more readily in these
cells. If apoptosis is induced after 3 days in culture, it is possible that this could be
brought on by either improper development of these cells due to increased pre-BCR/BCR
production as proposed earlier or inappropriate activation of immature B cells.
Overexpression of Pax-5e in B cells could lead to increased IgH rearrangement or
increased production o f pre-BCR components by increasing the activity of Pax-5a which
as mentioned before, has a critical role in these processes. If this leads to more rapid
maturity, it is possible that these cells may pass through IgH or IgL rearrangement
checkpoints prematurely, leading to proliferation of cells with inherent abnormalities in
their pre- or mature BCR. B cells which fail to properly rearrange their IgH or IgL chains,
respond to self antigen, or activate before maturity, will normally undergo apoptosis as a
part of the negative selection checkpoint (Hardy et al., 1991; reviewed in Liberg and
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Sigvardsson, 1999). If overexpression of Pax-5e leads to more rapid production of the
pre-BCR, rearrangement o f the Ig loci may not be completed properly. These
abnormalities would then lead to programmed cell death.
Another hypothesis is that increased Pax-5a activity may increase the likelihood
that precursor or immature B cells become activated through stimulation of their preBCR or BCR. As part of negative selection, any immature B cell activated by self
antigen or without antigen will undergo caspase-mediated apoptosis (reviewed in de
Alboran et al., 2003). If B cells overexpressing Pax-5e increase the production of a
mature BCR, some of these cells may show low affinity to self antigen or activate before
the mature BCR is established, thus leading to apoptosis. Based on this information, B
cells in TG5e-7 mice at any stage of development may undergo rapid expansion as a
result of increased Pax-5e levels, but succumb to negative selection during subsequent
stages (see model in Figure IV. 1).

Do increases in endogenous Pax-5e combined with transgenic overexpression
produce an additive effect in LPS-stimulated cells? Endogenous Pax-5e is normally
found at very low levels in resting B cell lines (Lowen et al., 2001). Previous
experiments in our lab have shown that Pax-5e levels increase 4-6 days after LPS
activation of normal resting B cells, indicating that antigenic stimulation results in
increased endogenous Pax-5e (Lowen et al., 2001). It is possible that the combination of
excess Pax-5e from the transgene with increased expression of endogenous Pax-5e
resulted in a more pronounced effect on proliferation than could be seen by each variable
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Figure IV. 1: A model portraying the effects of TG5e on proliferation and/or
apoptosis in developing B cells.
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independently. This would explain why the effects o f the transgene are more visible after
immunization. This was supported by earlier studies in our lab showing that increasing
amounts of transfected Pax-5e result in a dose-dependent increase in B cell growth and
proliferation (Beth Jones, unpublished data). This suggests that the actual concentration
of Pax-5e in B cells is important for cell proliferation. Thus, higher concentrations of
Pax-5e result in a greater increase in cell growth compared to lower concentrations of
Pax-5e.
In summary, TG5e-7 progeny appear to show increased proliferation in the early
stages of B cell development which may lead to increased apoptosis. More experiments
need to be performed to see if there is, in fact, a decrease in proliferation or an increase in
apoptosis or both on day 3. It would also be advantageous to look at individual cell
populations to determine at which stage the proliferative expansion is most prominent.
The cell populations to consider should include pro-B, pre-B, immature and mature B
cells as well as activated B cells, plasmablasts and plasma cells. Finally, any additive
effect from the combined levels of endogenous and transgenic Pax-5e during LPS
stimulation should be considered.

TG5e-49 bone marrow cells show increased proliferation in culture. TG5e-49
showed distinct increases in proliferation in the bone marrow after day 3 under LPSstimulated or unstimulated conditions. If we compare these data to that collected from
strain TG5e-7, it is possible to hypothesize that TG5e-49 cells are not undergoing the
same level o f selection or apoptosis seen in TG5e-7, and that more of these cells are
surviving after 3 days in culture. It is possible that a longer period of time in culture
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would reveal decreases in proliferation, but this would need to be tested. Also, the fact
that TG5e-49 expresses the transgene in both B cells and T cells could lead to changes in
bone marrow cell population growth. Since progenitor T cells are formed in the bone
marrow then migrate to the thymus, any effect on proliferation seen in the bone marrow
of TG5e-49 mice would be limited to the pro-T stage and all B cell stages. Assaying for
proliferation changes within the thymus of this strain is the next step that should be taken
to determine if T cell populations are proliferating as a result of Pax-5e expression.
The role of Pax-5 in proliferation has many applications in cancer research as the
pax genes as a whole are considered proto-oncogenes (Maulbecker & Gruss, 1993).
Translocation of the human pax-5 is associated with the onset of non-Hodgkin’s
lymphomas and acute leukemias (Zhang et al., 2003) and is also expressed in
neuroblastoma cells which are neural crest-derived tumors (Baumann-Kubetzko et al.,
2004). Earlier work has shown that overexpression of Pax-5 increased proliferation in
cultured splenic B cells activated by LPS, CD40 ligand or anti-IgD (Max et a l, 1995),
and as mentioned before, Pax-5e overexpression in mature B cell lines also resulted in an
increase in Pax-5a activity as well as an increase in B cell proliferation (Lowen et al.,
2001; Beth Jones, unpublished data). Given this information, it is conceivable that
overexpression of alternative isoform Pax-5e could also lead to similar tumor growth. As
was mentioned in the results, one of the founder mice, TG5e-31, succumbed to squamous
cell carcinoma. Also, there were 3 other founder mice that died before

8

unidentified causes.

Immunization enhances effects of TG5e in transgenic mice

weeks of age of
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TG5e-7 mice show increased Ig secretion and B cell numbers. Immunized TG5e-7
mice revealed a significant increase in IgM and IgG levels secreted by spleen cells, which
correlates well with ELISPOT data showing an increase in the number of IgG secreting
cells in the spleen and bone marrow. Although the ELISPOT data revealed a significant
increase in the number of Ig-secreting cells, the spot-size distribution remained
unchanged suggesting that there was no change in the individual populations of
plasmablasts or plasma cells (discussed in more detail below). Therefore, overexpression
of Pax-5e leads to increased numbers of Ig-secreting cells in spleen and bone marrow,
thus resulting in increased levels of secreted IgG and IgM in these organs.
Flow cytometry of immunized mice revealed an increase in pre- through mature B
cells (CD19+B220+) and (im)mature B cells (IgM+B220+) in the bone marrow o f the
transgenic mice. “Real time” PCR (qRT-PCR) showed no change in CD 19 expression in
the spleen, a characteristic also seen in the non-immunized mice. This could suggest that
the average spleen cell may be expressing less CD 19 in the transgenic mice than the
wild-type mice (maybe as a result of shifted frequencies of B cell subpopulations). An
increase in the production of (im)mature B cells (CD19+B220+ or IgM+B220+) in the
bone marrow of these mice likely results in the generation of more Ig-secreting cells after
immunization, as there are more mature B cells to be potentially activated by antigen. If
there is an increase in plasmablast/plasma cells in bone marrow, this would likely be the
cause of the increase in total secreted Ig seen via ELISA.
These data also relate to the previously described proliferation assays which
suggest that an increase in the level of Pax-5e results in increased B cell proliferation.
The question now becomes, what subpopulations of B cells show increased proliferation
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during an immune response? Based on the data acquired, we hypothesize that increased
levels of Pax-5e have lead to increased proliferation of pro/pre-B cells in the bone
marrow, resulting in increased numbers of (im)mature B cells (CD19+IgM+), which in
turn may contribute to an increase in plasma cells in the bone marrow and spleen. This is
supported by ELISPOT data that show an increase in all IgG secreting cells independent
of spot size.
Another possibility is that overexpression of Pax-5e in the plasmablast, the
proliferating intermediate between activated B cell and plasma cell, leads to increased
proliferation at this stage. Differentiation into CD 13 8 - plasmablasts results in extensive
proliferation as well as low levels o f Ig secretion, before the cells terminally differentiate
into plasma cells which cease to divide (Jego et al., 1999). Plasmablasts continue to
express low levels of Pax-5a as expression of BLIMP-1, a repressor of Pax-5a, begins to
increase, leading to terminal differentiation into a plasma cell and the complete silencing
o f the pax-5 gene (Lin et al., 2002). Since Pax-5a is still present at low levels in
plasmablasts, excess Pax-5e may be enhancing Pas-5a activity, resulting in continued
expression of Pax-5 a target genes, leading to increased plasmablast proliferation. Our
data show an increase in (im)mature B cells/plasmablasts (CD19+B220+ and
IgM+B220+) as well as increases in IgM/IgG expression seen in TG5e-7. From this, we
hypothesize that this increase in the number of (im)mature B cells and/or plasmablasts in
the bone marrow is due to excess proliferation at pro/pre-B cell or plasmablast stages.
In summary, the data collected on immunized TG5e-7 using several independent
approaches, imply that excess Pax-5e results in increased numbers of CD19+B220+ and
IgM+B220+ cells as well as increased numbers of Ig-secreting cells in the bone marrow.
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It would be interesting to use IgG as a marker in flow cytometry to see if this technique
shows an increase in the number of IgG+ mature B cells (memory B cells) and if this
correlates to the data collected using ELISPOT and ELISA to analyze plasma cell
populations. Also, plasma cell markers such as CD 138 used in flow cytometry would be
helpful to define changes in plasmablast or plasma cell populations to determine if they
support ELISPOT and ELISA data directly. Though proliferation assays of LPSactivated spleen and bone marrow cells showed no change in proliferation rate, it is
possible that an effect could emerge when immunized mice were used. Also, TNP was
the agent used to immunize the mice, not LPS, therefore comparisons between LPSactivated cultures and data from immunized mice should be considered, but not
necessarily used as a direct correlation. The data collected thus far from TG5e-7 provide
evidence for the hypothesis that increasing levels of Pax-5e enhance the activity of Pax5a and in turn, lead to increase cell proliferation (Lowen et al., 2001; Beth Jones,
unpublished data).

Immunized TG5e-49 mice show decreased B cell numbers and overexpression of
CD19. TG5e-49 mice displayed a very different phenotype after immunization compared
to TG5e-7 mice. We hypothesize that this difference is due to expression of the
transgene in both B and T cells in TG5e-49 as opposed to only B cells in TG5e-7 mice.
Progeny of strain TG5e-49 showed significantly decreased levels of secreted IgG in the
spleen as well as secreted IgM in the bone marrow (as shown by ELISA). ELISPOT data
indicated no change in the number of IgG-secreting cells; however, there appeared to be
relatively more smaller spots (cells secreting less IgG) and fewer larger spots (cells
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secreting more IgG) in the transgenic mice than in negative control mice. This was true
for bone marrow and spleen cell populations. This pattern suggests that even though the
number of IgG-secreting cells is the same in TG5e-49 mice, the amount of secreted IgG
per cell has decreased in the transgenic mice, resulting in the decrease seen by ELISA. A
possible explanation is that in the TG5e-49 there is a shift from plasma cells towards
plasmablasts which secrete less Ig and therefore produce smaller ELISPOTs. TG5e-49
mice show increased proliferation in the bone marrow cultures after 72 hours as well as a
significant increase in the number of pro-B cells (CD43+B220+) in the bone marrow of
immunized mice. This implies that, as with TG5e-7, increased proliferation of pro-B
cells produces increased numbers of (im)mature B cells which in turn lead to more
plasmablasts. Alternatively, the overexpression of Pax-5e may result in prolonged
proliferation of plasmablast populations and subsequent delays in the terminal
differentiation of plasma cells.
Quantitative RT-PCR also revealed a significant increase in CD 19 expression in
the spleen of TG5e-49 mice. An increase in CD 19 expression may indicate one of two
possibilities: 1) There are more CD 19+ B cells in a particular organ or 2) there are the
same number of B cells, or fewer, but more CD 19 molecules per cell. To answer this
question, we utilized flow cytometry to determine changes in the number of CD 19+ B
cells. Flow cytometry data indicated that there were fewer (im)mature B cells
(CD19+IgM+) in the spleen and bone marrow o f the transgenics. Thus the second
possibility, that there are fewer B cells, but with each B cell overexpressing CD 19, seems
most likely. If there is overexpression of CD 19 in TG5e-49 B cells, this could explain
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the increase in prolonged (3 day) proliferation seen in unstimulated and LPS-activated
bone marrow cells.
CD 19 is a cell surface protein involved in transducing signals from the BCR and
is believed to have a role in the proliferative expansion of pre-B I cells (large pre-B) after
the completion of the pre-BCR (Otero and Rickert, 2003). Mice lacking CD 19 (CD 19-/-)
show significant decreases in large pre-B cells in the bone marrow. Otero and Rickert’s
data was supported by BrdU incorporation measured by flow cytometry. The
investigators suggest that CD19’s role in proliferation may be to augment pre-BCR
signaling. Therefore, overexpression of CD 19 in our transgenic mice may initially
increase proliferation of pre-B cells by means of the pre-BCR, as indicated by increased
proliferation in LPS-stimulated bone marrow cultures. This increase in proliferation at
early B cell stages may result in increased apoptosis of cells with poorly formed BCRs or
inappropriately activated immature B cells, leading to fewer B cells during an immune
response. This also suggests that overexpression of Pax-5e could be enhancing 5a
activity, resulting in increased amounts of CD 19 and other proliferation genes, which
may collectively increase the proliferation rate of the cells at all developmental stages
whether they are stimulated or unstimulated.

The effects of Pax-5e on B and T cell development in TG5e mice. RT-PCR analysis
on purified B and T cells from the spleens of TG5e-49 progeny and negative littermate
controls showed that this strain expresses the transgene in both B and T cells. We were
also able to show Pax-5e protein overexpression in the thymus of TG5e-49 mice (see
Figure II.2E). The latter is not surprising as this construct had been shown to express in
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B as well as in T lymphocytes (Pircher et al., 1989; Malek et al., 1998). Flow cytometry
revealed a significant decrease in the number of CD3+ T cells in the spleen of immunized
TG5e-49 progeny and, though there was a decrease in the thymus, these data were not
significant. This leads us to believe that overexpression of Pax-5e in T cells has negative
consequences for development, specifically during activation of T cells as no changes
were seen in unimmunized mice. No further work has been done on this aspect of TG5e49; however, possible experiments are being considered. Most importantly, the
availability of T cells expressing Pax-5e in the absence o f Pax-5a will be a valuable tool
to study Pax-5a-independent role(s) of Pax-5e in proliferation.
Pax-5a is not normally expressed in T lymphocytes (Adams et al., 1992),
therefore there must be some other molecule present in the T cell for Pax-5e to interact
with in order to produce the effects seen in the T cell populations of TG5e-49. There are,
however, endogenous interaction candidates present in T cells that could interact with
Pax-5 e. One of those candidates is thioredoxin (TRX) which is up-regulated within T
cells during oxidative stress by H 2O2 (Kondo et al., 2004). The data from this thesis do
not prove an interaction between Pax-5e and TRX in T cells, thus the following
hypotheses are speculative; inferred from other TRX studies.
TRX interacts with redox factor-1 (Ref-1) to activate the AP-1 transcription factor
during oxidative stress or ionizing radiation treatments (Wei et al., 2000). TRX, Ref-1
and AP-1 are active in T cells as well as B cells (Tell et al., 2000; Wei et al., 2000).
Previous research in our lab has shown that Pax-5e interacts with a small protein,
possibly forming a heterodimer (Lowen et al., 2001). Experiments have revealed that a
thioredoxin-like protein co-immunoprecipitates with Pax-5e and is detected by a catfish
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monoclonal anti-TRX (IgA) antibody. These immunoprecipitation experiments also
show that as Pax-5e levels increase after 4-6 day stimulation of B cell lines with LPS, the
level of TRX that co-immunoprecipitates with Pax-5e also increases.
TRX lacks a nuclear localization sequence (NLS) and is thought to be shuttled
into the nucleus via another protein, as the exact means of nuclear localization is
unknown (Powis et al., 2001). Our lab proposed that interactions with Pax-5e, which
does have an NLS, allow for TRX to be shuttled into the nucleus in order to interact with
such factors as Ref-1 and AP-1 (Lowen et al., 2001). Based on the 3D structure and
physiochemical properties of the Pax-5e novel sequence, bioinformatics and 3D protein
structure software have predicted this sequence to be ideal for interaction with TRX
(Cuperlovic-Culf et al., 2003). Also, the transcription factor AP-1 interacts with nuclear
factor of activated T cell (NFAT) during T cell activation by binding as a heterodimer to
composite elements of a promoter region in order to activate genes such as IL-2 and IL-5
(Kel et al., 1999). TRX typically responds to oxidative stress by inducing the activation
of NF-kB or up-regulating intracellular antioxidants like glutathione (Nakamura et al.,
1997). As TRX interacts with AP-1, and possibly NF-kB, it may play a role in
regulating apoptosis pathways of activated or oxidatively stressed cells. Therefore, if
TRX and Pax-5e do in fact interact, effects of Pax-5e within a T cell are most likely
initiated by the activation of the T cell during immunization, as AP-1/NFAT are active
during T cell activation. Since Pax-5e is normally absent in a T cell system, this alone
may cause perturbations in cell activation, possibly leading to increased apoptosis (see
proposed model Figure IV.2).
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Interactions of Pax-5e in T cells of TG5e-49
TRX interacts with and
activates R ef-1 leading to
an activation o f AP-1

Pax-5e
translocates
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nucleus

AP-1

Ref-1

Ref-1
TRX
Pax-5 e
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Figure IV.2: Model of Pax-5e interaction in T cells. The presence of Pax-5e in T cells
enhances the activation process of T cells during an immune response by shuttling excess
TRX (hatched octagon) into the nucleus. Once in the nucleus, TRX interacts with Ref-1
(triangle) which allows Ref-1 to activate AP-1 (inactivated=parallelogram). Activated
AP-1 (square) binds NFAT (oval) and the heterodimer situates on promoter regions of
activation-induced T cell genes causing expression of genes such as IL-2 and IL-5.
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Interactions between Pax-5e and TRX have implications for B cell development
in both B and T cell overexpressing strains. Studies have suggested that Pax-5a functions
most efficiently in a reduced form as treatment of cells with H 2O 2 reduces Pax-5 DNAbinding activity in vivo (Tell et al., 2000). These data were supported by initial studies
using recombinant Pax-5a and Pax - 8 paired domains that revealed evidence for redox
regulation through the conserved cysteine residues present in that region of the protein
(Tell et al., 1998). This leads us to believe that overexpression of Pax-5e could cause
increased reduction of Pax-5a thus leading to increased Pax-5a DNA-binding activity. A
proposed model shows Pax-5e interacting with TRX thus inducing both the reduction of
Pax-5e and the translocation of TRX into the nucleus. Once in the nucleus, Pax-5e then
reduces Pax-5a causing an increase in DNA-binding activity and subsequently an
increase in target gene expression, specifically in this case of proliferation genes such as
blk (refer back to Figure 1.4).

Future Directions
Our data provide evidence that Pax-5e enhances the activity of Pax-5a in B cells.
This activity results in changes in cell proliferation and activation in normal and
immunized transgenic mice and negative littermate controls. We also suggest that Pax-5e
has a profound affect on the growth and development of T cells during an immune
response, possibly by interacting with endogenous T cell factors such as TRX. Recently,
it was discovered that the human pax-5 gene is alternatively spliced resulting in five
novel isoforms (Robichaud et al., 2004). These isoforms differ from the murine isoforms
in that all retain the ability to bind DNA, but come about by splicing out different
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combinations of exons 7,

8

and 9. It would be interesting to now compare the functions

of these structurally different isoforms to the murine Pax-5 isoforms. Do the human Pax5 isoforms have a role in cell proliferation? Do they interact with one another?
There are many avenues that could be taken to expand on the data presented in
this thesis. The most important experiments will need to include isolation of
subpopulations o f B cells into progenitor, precursor, (im)mature B cells as well as
activated B cells, plasmablasts and plasma cells. These subpopulations are critical for
analyses in both strains, however T cell subpopulations will need to be purified for TG5e49. Once we have these populations of cells, we can look at changes in proliferation rates
(for both LPS-stimulated and unstimulated cells), as well as changes in specific lymphoid
population sizes and distributions via flow cytometry. Some of the necessary markers for
flow cytometry include CD4 and CD 8 for T cells as well as T cell progenitor markers,
pre-BCR components for late progenitor and early precursor B cells, and CD 138 for
plasma cells.
Due to time and resources, we were unable to investigate the effects of TG5e on
the expression of blk, one of the key proliferation genes in the B cell. Thus, future
studies should include “real time” PCR analysis of blk expression in normal and
immunized mice of both strains. Since blk is a target gene of Pax-5 a, if it is
overexpressed in our transgenic mice this would provide further evidence for our
hypothesis that Pax-5e leads to increased proliferation by enhancing Pax-5a activity.
Other target genes of Pax-5 a should be considered as well such as mb-1, XBP-1, and cmyc as well as components of the pre-BCR.
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Further studies on TG5e-49 may provide insight into Pax-5 e interactions with
TRX as well as Pax-5a-independent proliferation. Focusing on genes affected by active
TRX in T cells may allow for analysis by CAT assays or EMSA to determine if AP-1
binding to target genes is increased transgenic mice. Overexpression of AP-1 target
genes may be investigated through the use of “real time” PCR.
Our studies using the murine Pax-5 isoforms will hopefully shed light on the roles
o f their human counterparts and further develop models for cell proliferative disorders
such as lymphoma, leukemias, and multiple myelomas. Though there is still much more
work involved in this project, the opportunities of future experimentation are bountiful
and the applications are promising.
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